EP3023081A1 - Intragastric implants with multiple fluid chambers - Google Patents
Intragastric implants with multiple fluid chambers Download PDFInfo
- Publication number
- EP3023081A1 EP3023081A1 EP15202671.2A EP15202671A EP3023081A1 EP 3023081 A1 EP3023081 A1 EP 3023081A1 EP 15202671 A EP15202671 A EP 15202671A EP 3023081 A1 EP3023081 A1 EP 3023081A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- implant
- balloon
- stomach
- inflatable
- inflatable balloon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
- A61F5/0013—Implantable devices or invasive measures
- A61F5/003—Implantable devices or invasive measures inflatable
- A61F5/0033—Implantable devices or invasive measures inflatable with more than one chamber
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
- A61F5/0013—Implantable devices or invasive measures
- A61F5/0036—Intragastrical devices
Abstract
Description
- The present application claims priority under 35 U.S.C. §119 to
U.S. Provisional Application No. 61/478,013, filed April 21, 2011 U.S. Provisional Application 61/394,685, filed October 19, 2010 U.S. Provisional Application No. 61/394,592, filed October 19, 2010 - The present invention generally relates to intragastric implants used for the treatment of obesity, and in particular to inflatable implants and systems for placement in the stomach cavity that provide flow between multiple chambers.
- Over the last 50 years, obesity has been increasing at an alarming rate and is now recognized by leading government health authorities, such as the Centers for Disease Control (CDC) and National Institutes of Health (NIH), as a disease. In the United States alone, obesity affects more than 60 million individuals and is considered the second leading cause of preventable death. Worldwide, approximately 1.6 billion adults are overweight, and it is estimated that obesity affects at least 400 million adults.
- Obesity is caused by a wide range of factors including genetics, metabolic disorders, physical and psychological issues, lifestyle, and poor nutrition. Millions of obese and overweight individuals first turn to diet, fitness and medication to lose weight; however, these efforts alone are often not enough to keep weight at a level that is optimal for good health. Surgery is another increasingly viable alternative for those with a body mass index (BMI) of greater than 40. In fact, the number of bariatric surgeries in the United States was estimated to be about 400,000 in 2010.
- Examples of surgical methods and devices used to treat obesity include the LAP-BAND® (Allergan, Inc., Irvine, CA) gastric band and the LAP-BAND AP® (Allergan, Inc., Irvine, CA) gastric band. However, surgery might not be an option for every obese individual; for certain patients, non-surgical therapies or minimal-surgery options are more effective or appropriate.
- Intragastric balloons are also well known in the art as a means for treating obesity. One such inflatable intragastric balloon is described in
U.S. Patent No. 5,084,061 and is commercially available as the Orbera® System from Allergan Medical of Irvine, CA. These devices are designed to provide therapy for moderately obese individuals who need to shed pounds in preparation for surgery, or as part of a dietary or behavioral modification program. - The Orbera® System, for example, consists of a silicone elastomer intragastric balloon that is inserted into the stomach in an empty or deflated state and thereafter filled (fully or partially) with a suitable fluid. The balloon occupies space in the stomach, thereby leaving less room for food and creating a feeling of satiety for the patient. Placement of the intragastric balloon is non-surgical, trans-oral, usually requiring no more than 20-30 minutes. The procedure is performed gastroscopically in an outpatient setting, typically using local anesthesia and sedation. Intragastric balloons typically are implanted for a finite period of time, up to six months. Removing the balloon requires deflation by puncturing with a gastroscopic instrument, and either aspirating the contents of the balloon and removing it, or allowing the fluid to pass into the patient's stomach. Clinical results with these devices show that for many obese patients, the intragastric balloons significantly help to control appetite and accomplish weight loss.
- Some attempted solutions for weight loss by placing devices in the stomach result in unintended consequences. For instance, some devices tend to cause food and liquid to back up in the stomach, leading to symptoms of gastroesophageal reflux disease (GERD), a condition in which the stomach contents (food or liquid) leak backwards from the stomach into the esophagus. Also, the stomach acclimates to some gastric implant devices, leading to an expansion of stomach volume and consequent reduction in the efficacy of the device.
- Despite the advances in the design of intragastric balloons, there remains a need for improved intragastric obesity treatment implants that provide more varied stimulation.
- The present invention addresses the above-described problems by providing intragastric apparatuses and methods for inducing satiety and therefore treating obesity. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, a number of devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.
- One intragastric obesity treatment implant disclosed herein comprises a first inflatable balloon configured to be disposed in a patient's stomach, wherein the first inflatable balloon is configured to be inflated with a fluid after implantation in the patient's stomach. A second inflatable balloon fluidly couples to the first inflatable balloon such that the inflatable balloons have a longitudinal length that substantially spans the stomach and the second inflatable balloon is positioned adjacent the cardia, wherein the second inflatable balloon is configured to be inflated with a fluid after implantation in the patient's stomach. A flow restrictor interposed between the first and second inflatable balloons regulates flow therebetween. In response to peristaltic inward pressure from the stomach proximate the first inflatable balloon, a portion of the fluid moves from the first inflatable balloon through the flow restrictor into the second inflatable balloon and causes the second inflatable balloon to expand to exert pressure on the cardia and induce a feeling of satiety in the patient.
- The first inflatable balloon and the second inflatable balloon may comprise a plurality of external grooves oriented along an axis connecting the two balloons and configured to allow ingested food to pass by so that the ingested food may be digested by the patient. The first and second inflatable balloons may have eight grooves each. In one embodiment, the flow restrictor comprises a narrow portion connecting the first inflatable balloon and the second inflatable balloon, and further including an elastic band wrapped around the narrow portion. Alternatively, wherein the flow restrictor comprises a narrow portion connecting the first inflatable balloon and the second inflatable balloon, and the narrow portion includes fluted wings configured to provide structural support to the narrow portion.
- The implant may further include a single evacuation valve that may be accessed with an aspirator to simultaneously evacuate both the first and second inflatable balloons. In one form, the implant has a dog-bone shape, with identical first and second inflatable balloons defining enlarged outer ends joined by a smaller middle portion. Also, the first and second inflatable balloons may each include an inner end wall diametrically-oriented with respect to the longitudinal axis, the end walls being joined in abutting relationship to form a partition in the implant, and wherein the flow restrictor comprises fluid passageways across the partition. A valve may be positioned in the partition that permits flow from the first inflatable balloon to the second inflatable balloon but prevents reverse flow therebetween, the valve having a flow rate capacity greater than the fluid passageways of the flow restrictor. The first and second inflatable balloons may have a generally uniform longitudinal exterior shape.
- In one embodiment, the second inflatable balloon is at least three times the volume of the first inflatable balloon. Desirably, the combined volumes of the first and second inflatable balloons is at least about 400 ml of saline. The implant may further including a tether having a first fluid passage fluidly connecting the first and second inflatable balloons and having the flow restrictor therein. The tether may include two passages, the first fluid passage being open between the first and second inflatable balloons and a second passage having one-way flow valves therein at each end adjacent each of the first and second inflatable balloons that prevent fluid from traveling from the second passage into the respective first or second inflatable balloon but permit flow from the respective first or second inflatable balloon into the second passage upon a predetermined pressure differential thereacross. The first fluid passage preferably has a size that permits a maximum flow rate of about 1-20 ml/s.
- The implant may also include a third inflatable balloon positioned between the first and second inflatable balloons, the third inflatable balloon having a fixed volume and not being freely fluidly connected to the first and second inflatable balloons. The third inflatable balloon preferably comprises a larger balloon than either of the first and second inflatable balloons, wherein the first and second inflatable balloons fluidly communicate with each other via a communication tube extending through the third inflatable balloon. A relief valve may be provided on the communication tube and within the third inflatable balloon that opens from a threshold pressure from the connected first and second inflatable balloons to vent fluid into the third inflatable balloon.
- Another aspect of the application is an intragastric obesity treatment implant having an outer inflatable balloon configured to be disposed in a patient's stomach, wherein the outer inflatable balloon is configured to be inflated with saline after implantation in the patient's stomach and having a length oriented along a longitudinal axis that substantially spans the stomach such that a first end of the implant is positioned adjacent the antrum and a second end of the implant is positioned adjacent the cardia. A core balloon located within the outer inflatable balloon contains air without leaking so as to occupy volume within the outer inflatable balloon. The core balloon includes an upper portion residing within the second end of the outer balloon, and a lower portion residing within the first end of the outer balloon having a smaller internal volume than the upper portion such that the greater buoyancy of the upper portion tends to orient the second end of the outer balloon at the top of the stomach cavity adjacent the cardia.
- The upper portion may be formed as a monolithic bladder and the lower portion of the core balloon comprises a series of elongated longitudinally-oriented bladders fluidly connected to the single monolithic bladder. The outer inflatable balloon preferably includes first and second inflatable balloons respectively defining the first and second ends of the implant and separated from each other by a one-way valve and a series of fluid passageways. The one-way valve permits fluid flow of a predetermined maximum rate from the first inflatable balloon to the second inflatable balloon and the fluid passageways permitting fluid flow in the opposite direction from the second inflatable balloon to the first inflatable balloon at a rate less than the predetermined maximum rate. Consequently, in response to peristaltic inward pressure from the stomach proximate the first inflatable balloon, a portion of the fluid moves from the first inflatable balloon through the one-way valve into the second inflatable balloon and causes the second inflatable balloon to expand to exert pressure on the cardia and induce a feeling of satiety in the patient.
- In one embodiment, each of the first and second inflatable balloons includes an inner end wall diametrically-oriented with respect to the longitudinal axis, the end walls being joined in abutting relationship to form a partition in the implant, and wherein the one-way valve and fluid passageways cross the partition. The core balloon may span the partition. The implant may further have an outer fill valve in the outer inflatable balloon at the first end of the implant with an outlet aperture projecting within the outer inflatable balloon and toward an inner fill valve in the core balloon such that a single fill tube may be used to inflate both the inner core balloon with air and the outer inflatable balloon with saline.
- An alternative embodiment of an intragastric obesity treatment implant comprises a pumping chamber configured to pump a fluid within a patient's stomach, wherein the fluid enters the pumping chamber via a hole disposed in the pumping chamber. A first reservoir couples to the pumping chamber via first tubing, and a first fill valve disposed in the first reservoir couples to the first tubing to regulate the flow of the fluid from the pumping chamber to the first reservoir. Consequently, a peristaltic motion of the patient's stomach compresses the pumping chamber causing the fluid to exit the pumping chamber through the first tubing and the first fill valve into the first reservoir. The implant also has a first release valve disposed in the first reservoir, wherein the first release valve is configured to release a portion of the fluid from the first reservoir when a first predetermined condition is reached in the first reservoir.
- A still further intragastric obesity treatment implant disclosed herein has a flexible pumping chamber with a fill valve and configured to be inserted transorally into a patient's stomach in a deflated state and inflated with a fluid through the fill valve. First and second flexible reservoirs each separately fluidly couple to the pumping chamber via an open fluid transfer lumen. A fill valve fluidly disposed in a fluid lumen between each of the first and second reservoirs and the pumping chamber permits the flow of the fluid from the pumping chamber to the respective reservoir but prevents flow in the opposite direction.
- In either of the preceding two implants with pumping chambers, a second reservoir may be provided comprising a second fill valve, wherein the second reservoir is coupled to the pumping chamber via second tubing. The pumping chamber, the first reservoir, and the second reservoir may be coupled in series or in parallel. The first fill valve and the second fill valve may individually comprise at least one of a one-way valve, a duckbill valve, or a ball check valve. Preferably, at least one of the first reservoir or the second reservoir comprises a compliant reservoir that expands in response to the fluid entering the compliant reservoir, wherein the expanding compliant reservoir generates an increased pressure in the compliant reservoir. The implant may have a second release valve disposed in the second reservoir to release a second portion of the fluid from the second reservoir when a second predetermined condition is reached in the second reservoir. The first release valve and the second release valve may individually comprise at least one of a flow restrictor, a burp valve, or a burst valve. The first predetermined condition and the second predetermined condition individually comprise at least one of a predetermined pressure, a predetermined shape, or a predetermined size.
- In some cases, a wall of the patient's stomach covers the hole during the peristaltic motion to cause the fluid to exit the pumping chamber via the first tubing. Or, a wall of the patient's stomach covers the hole during the peristaltic motion to prevent the fluid from exiting the hole. The pumping chamber desirably comprises a plurality of holes. The pumping chamber is preferably configured to return to an expanded state after the peristaltic motion ceases, and wherein the pumping chamber draws the fluid into the pumping chamber through the hole when the pumping chamber returns to the expanded state.
- In one embodiment, the pumping chamber includes an open celled foam structure to cause the pumping chamber to return to the expanded state. The pumping chamber may also comprise thick walls that cause the pumping chamber to return to the expanded state. The pumping chamber may further comprise a chamber tube disposed through the pumping chamber to cause the pumping chamber to return to the expanded state. In one form, the chamber tube is coupled to the first tubing and comprises a chamber tube hole to allow the fluid to pass from the pumping chamber into the chamber tube and through the first tubing into the first reservoir.
- The fluid may be saline, and the volume of the pumping chamber is between about 400-600 ml. Each of the fluid transfer lumens preferably has a size that permits a maximum flow rate of about 1-20 ml/s. The implant may further include a connector between each of the first and second reservoirs and the pumping chamber, including a threaded coupling through which the fluid transfer lumen and the fluid lumen pass. The fluid transfer lumen may be substantially smaller in size than the fluid lumen such that fluid flows faster from the pumping chamber to the reservoirs than in the reverse for a given pressure differential.
- In another embodiment, an intragastric obesity treatment implant comprises a first inflatable balloon configured to be disposed in a patient's stomach, wherein the first inflatable balloon is configured to be inflated with a fluid after implantation in the patient's stomach. A second inflatable balloon couples to the first inflatable balloon such that the inflatable balloons have a longitudinal length that substantially spans the stomach and the second inflatable balloon is positioned adjacent the cardia, wherein the second inflatable balloon is configured to be inflated with a fluid after implantation in the patient's stomach. A flow restrictor interposed between the first and second inflatable balloons is adapted to regulate flow therebetween. In response to peristaltic movement of the stomach proximate the first inflatable balloon, a portion of the fluid moves from the first inflatable balloon through the flow restrictor into the second inflatable balloon and causes the second inflatable balloon to expand to exert pressure on the cardia and induce a feeling of satiety in the patient.
- Further, in an embodiment, an intragastric obesity treatment implant comprises a pumping chamber configured to pump a fluid within a patient's stomach. The fluid enters the pumping chamber via a hole disposed in the pumping chamber. A reservoir is coupled to the pumping chamber via tubing, and a fill valve is disposed in the reservoir and coupled to the tubing to regulate the flow of the fluid from the pumping chamber to the reservoir. The peristaltic motion of the patient's stomach compresses the pumping chamber causing the fluid to exit the pumping chamber through the tubing and the fill valve into the reservoir. A release valve is disposed in the reservoir, and the release valve is configured to release a portion of the fluid from the reservoir into the patient's stomach when a predetermined condition is reached in the reservoir.
- A further understanding of the nature and advantages of the invention will become apparent by reference to the remaining portions of the specification and drawings.
-
-
FIG. 1 illustrates a side view of an intragastric obesity treatment implant with two grooved balloons in a patient's stomach in accordance with an embodiment of the present application. -
FIG. 2 illustrates a perspective view of an intragastric obesity treatment implant with two grooved balloons similar toFIG. 1 . -
FIG. 3 illustrates a perspective view of an intragastric obesity treatment implant with two grooved balloons and a flow restrictor similar toFIG. 1 . -
FIG. 4 illustrates an end view of the grooved intragastric obesity treatment implant balloon ofFIG. 3 . -
FIG. 5 illustrates a sectional side view of the intragastric obesity treatment implant with a flow restrictor ofFIG. 3 . -
FIG. 6A illustrates a perspective view of an intragastric obesity treatment implant with center flanges and an end plug in accordance with an embodiment of the present application. -
FIG. 6B illustrates a perspective view of an intragastric obesity treatment implant with center flanges and a fill valve as inFIG. 6A . -
FIG. 7A illustrates a perspective view of an intragastric obesity treatment implant with eight center wings and an end plug in accordance with an embodiment of the present application. -
FIG. 7B illustrates a perspective view of an intragastric obesity treatment implant with eight center wings and a fill valve as inFIG. 7A . -
FIG. 8A illustrates a side view of an intragastric obesity treatment implant with a pumping chamber and two reservoirs in a patient's stomach in accordance with an embodiment of the present application. -
FIG. 8B illustrates a side view of an intragastric obesity treatment implant with a pumping chamber as inFIG. 8A being compressed by a patient's stomach. -
FIG. 9 illustrates a perspective view of tri-balloon intragastric obesity treatment implant with a pumping chamber, two reservoirs, one-way valves, and flow restrictors in accordance with an embodiment of the present application. -
FIG. 10A illustrates a sectional view of a reservoir with an open one-way valve for use in an implant such asFIG. 9 . -
FIG. 10B illustrates a sectional view of a reservoir with a closed one-way valve as inFIG. 10A . -
FIGS. 11A-11C illustrate sectional views of a reservoir with a burp valve in accordance with an embodiment of the present application. -
FIGS. 12A-12B illustrate sectional views of a pumping chamber with a chamber tube in accordance with an embodiment of the present application. -
FIGS. 13A-13B illustrate sectional views of a pumping chamber with open-celled foam in accordance with an embodiment of the present application. -
FIGS. 14A-14B illustrate sectional views of a one-way duckbill valve for use in implants of the present application. -
FIGS. 15A-15B illustrate sectional views of a one-way ball check valve for use in implants of the present application. -
FIG. 16 illustrates an alternative tri-balloon intragastric obesity treatment implant of the present application implanted in a stomach. -
FIGS. 17A-17B illustrate details of the tri-balloon intragastric obesity treatment implant ofFIG. 16 -
FIG. 18 illustrates a side view of an intragastric obesity treatment implant with two inflated and fluidly-connected balloons in a patient's stomach in accordance with an embodiment of the present application. -
FIG. 19A illustrates a sectional side view of an intragastric obesity treatment implant as inFIG. 18 showing a flow restrictor within a connecting tether. -
FIG. 19B is a detail of the connecting channel fromFIG. 19A showing the flow restrictor and a deflation assembly. -
FIG. 20 shows an alternative dual-balloon intragastric obesity treatment implant with two inflated and fluidly-connected balloons in a patient's stomach. -
FIGS. 21A-21B illustrate details of the dual-balloon intragastric obesity treatment implant as inFIG. 20 . -
FIG. 22A illustrates a side view of an intragastric obesity treatment implant with an inflated pumping chamber fluidly-connected to two reservoirs on opposite ends in a patient's stomach in accordance with an embodiment of the present application. -
FIG. 22B illustrates a side view of the intragastric obesity treatment implant inFIG. 22A with the pumping chamber being compressed by a patient's stomach to fill the two reservoirs. -
FIG. 23 is a sectional view of the intragastric obesity treatment implant inFIG. 22A showing one-way valves and flow restrictors between the pumping chamber and two reservoirs. -
FIG. 24 is a detailed sectional view of a one-way valve and flow restrictor between the pumping chamber and one of the two reservoirs in the intragastric obesity treatment implant ofFIG. 22A . -
FIGS. 25A-25B illustrate an alternative intragastric obesity treatment implant positioned within a patient's stomach and in sectional view, the intragastric obesity treatment implant having dual connected balloons in a dog bone configuration with a partition and fluid transfer therebetween. -
FIG. 26A show an alternative dual-balloon intragastric obesity treatment implant similar to that inFIGS. 25A-25B with a more uniform longitudinal shape and positioned within the stomach, whileFIG. 26B illustrates contraction of the stomach walls to squeeze fluid from a lower balloon to an upper balloon. -
FIGS. 27-29 are various views of a concentric chamber inflatable intragastric obesity treatment implant of the present application having an outer saline-filled chamber and an inner air-filled chamber. -
FIGS. 30A-30D illustrate perspective views of intragastric obesity treatment implants with various configurations of pumping chambers, tubing, and reservoirs in accordance with various embodiments of the present application. -
FIGS. 31-33 illustrate intragastric implant surface features that provide additional stomach cavity stimulation. - In accordance with various embodiments of the present application, intragastric obesity treatment implants generally comprise an implant that occupies space in a patient's stomach. The space occupied by the intragastric obesity treatment implant reduces the available volume in the stomach that may be occupied by ingested food. Accordingly, a patient with the intragastric obesity treatment implant in the stomach may experience a feeling of satiety while consuming less food than before the device was implanted. This reduced food intake may allow the patient to lose weight.
- Furthermore, some embodiments disclosed herein may exert pressure on the upper portion of the stomach, or the cardia. This pressure may induce early feelings of satiety by triggering the patient's brain to release satiety-inducing hormones. These hormones may cause the patient to stop eating sooner, also resulting in weight loss.
- By way of example, the present disclosure will reference and discuss certain intragastric obesity treatment implants. Nevertheless, persons skilled in the art will readily appreciate that concepts disclosed herein may be advantageously applied to arrive at other intragastric obesity treatment implants without departing from the scope of the present invention.
- Various embodiments allow for the intragastric obesity treatment implants to be implanted in the patient's stomach transorally -- through the patient's mouth and down the patient's esophagus. As such, the intragastric obesity treatment implants may be referred to as transoral implants and/or transoral intragastric obesity treatment implants. Transoral implantation advantageously allows implantation of the intragastric obesity treatment implant without associated patient risks of invasive surgery and without substantial patient discomfort. Recovery time after implantation of the transoral intragastric obesity treatment implant may be minimal as no extensive tissue healing is generally required. The life span of these implants may be material-dependent upon long-term survivability within an acidic stomach, but various embodiments are advantageously configured to last one year or longer.
-
Figure 1 illustrates a first space-occupyingimplant 8, but also illustrates the anatomy of the human stomach, which will be described first. The major function of the stomach is to temporarily store food and release it slowly into the duodenum. The esophagus extending downward from the mouth connects to the stomach via esophageal sphincter, which regulates flow food into the stomach cavity. The cardia surrounds the superior opening of the stomach. The rounded portion superior to the body and adjacent the cardia is the fundus. Inferior to the fundus is the large central portion of the stomach, called the body, that is lined with muscles that contract and relax repetitively to churn the food therein. The stomach processes the food to a semi-solid "chyme," which enables better contact with the mucous membrane of the intestines, thereby facilitating absorption of nutrients. In addition, the stomach is an important site of enzyme production. - Lower down in the stomach the antrum connects the body to the pylorus, which leads into the duodenum. Below the stomach, the duodenum leads into the upper part of the small intestine (not shown); the jejunum makes up about one-third of the small intestine. The region of the stomach that connects to the duodenum is the pylorus. The pylorus communicates with the duodenum of the small intestine via the pyloric sphincter (valve). This valve regulates the passage of chyme from stomach to duodenum and it prevents backflow of chyme from duodenum to stomach.
- In accordance with further embodiments of the present invention, and with reference to
FIGS. 1-5 , an intragastricobesity treatment implant 8, such as an active balloon adipose trimming element, comprises a gastrointestinal implant with two lobes and/orballoons balloons - The intragastric
obesity treatment implant 8 may be configured to be implanted in the patient's stomach S, transorally, without invasive surgery, and without associated patient risks of invasive surgery. Recovery time may be minimal because of reduced tissue healing post implantation. In an embodiment, the intragastricobesity treatment implant 8 may have a product life span in the stomach S of up to one year or longer. As will be discussed, the intragastricobesity treatment implant 8 facilitates weight loss and obesity treatment through adipose trimming and/or fat reduction due to the patient consuming less food. - The intragastric
obesity treatment implant 8 comprises an active system where theballoons obesity treatment implant 8 is configured to span the upper and lower stomach regions, ranging from the antrum to the cardia. - In addition to occupying space in the stomach S, the intragastric
obesity treatment implant 8 may be configured to actively facilitate obesity treatment through early inducement of feelings of satiety and resulting reduced food consumption. For example, in an embodiment, a fluid is disposed in theballoons balloons center portion 17 that couples theballoon 10 to theballoon 12. Thecenter portion 17 comprises a passageway that allows the fluid to pass between theballoons - After ingestion of food by the patient, peristaltic digestive "churning" of the stomach S begins. These peristaltic motions cause various portions of the stomach S to repeatedly contract and relax to move food through the stomach S. Based on the geometry of the stomach S and the intragastric
obesity treatment implant 8, the peristaltic motions near the lower balloon 12 (disposed near the antrum) may cause the stomach S to squeeze theballoon 12. As theballoon 12 is squeezed, fluid passes from theballoon 12, through thecenter portion 17, and into the upper balloon 10 (disposed near the cardia). Theupper balloon 10 may comprise a compliant material, such that the increased amount of fluid in theballoon 10 causes theballoon 10 to expand and exert increased pressure on the cardia. This increased pressure on the cardia may induce early feelings of satiety by triggering the brain to release satiety-inducing hormones, so eating will likely cease and weight loss may ensue. - In accordance with various embodiments, after digestion, the peristaltic motions in the stomach cease, resulting in reduced pressure exerted on the
balloon 12. This reduced pressure exerted on theballoon 12, in conjunction with the increased pressure in theballoon 10 from the increased amount of fluid in the balloon 10 (and due to forces induced in the expanded compliant material in theballoon 10 from expansion), causes the fluid in theballoon 10 to return to theballoon 12 via thecenter portion 17 until the pressure is substantially equalized between the twoballoons - The return flow from the
balloon 10 to theballoon 12 may be slowed down to maintain an expanded size of theballoon 10 for a longer period of time. For example, the passageway in thecenter portion 17 may be advantageously configured to have a sufficient size to allow for a desired flow rate. In an embodiment, the passageway may be a through hole having a diameter of approximately one millimeter. In another embodiment, a center band 19 (e.g., an elastic band) may be disposed around thecenter portion 17 as a flow restrictor to appropriately reduce the size of the passageway and constrict for a desired flow rate. Other flow restrictor devices such as valves, pressure reducers and the like and combinations thereof may be utilized to allow for a desired flow rate between theballoons - In various embodiments, the intragastric
obesity treatment implant 8 may comprise a plurality of flutes, ridges, and/orgrooves 15 that are configured to prevent obstruction of food as it moves through the pylorus and into the duodenum of the patient. Thegrooves 15 direct the food to pass by theimplant 8 along the stomach S walls. For example, in an embodiment as illustrated inFIG. 4 , eachballoon grooves 15 to direct the food flow. However, it should be understood that any number ofgrooves 15 that facilitate appropriate passage of food are contemplated within the scope of the present invention. The ends of thegrooves 15 near thecenter portion 17 may be flush with the surrounding surface of theballoons balloons - With reference also to
FIGS. 6-7 , and in accordance with further embodiments, the intragastricobesity treatment implant 8 may be formed in a "dog bone" shape with enlarged ends and strengthening structure, such as a flange orwing 20 disposed along thenarrower center portion 17. Although the embodiments inFIGS. 6-7 are different than those shown inFIGS. 1-5 , certain common features will be given the same element numbers for clarity. The wing orwings 20 may prevent kinking of thecenter portion 17 in order to maintain the passageway in thecenter portion 17 open. For example, with reference specifically toFIGS. 6A-6B , fourwings 20 may be configured in an "X" shape along thecenter portion 17 in accordance with an embodiment. In another embodiment, and with reference specifically toFIGS. 7A-7B , eightwings 20 may be disposed along thecenter portion 17 to provide structure to thecenter portion 17 and/or to prevent kinking. It should be understood that various other configurations of thewings 20 and/or other structures may be utilized to provide support to thecenter portion 17 and/or to prevent kinking, without departing from the scope of the present invention. - With continued reference to
FIGS. 6-7 , and in accordance with various embodiments, theballoon 10 may comprise afill valve 24 to allow the intragastricobesity treatment implant 8 to be filled with saline after implantation of the implant in the stomach S. Theballoon 12 may similarly have anend plug 22 to prevent saline from exiting theballoon 12. Thus, the intragastricobesity treatment implant 8 may be disposed in the stomach S via the esophagus in a substantially non-inflated state. In this manner, a lubricated, thin-walled tube, such as a tube made with Teflon or a similar material may be inserted through the patient's mouth, down the esophagus, and partially into the stomach S. Theimplant 8 in a compressed state may be preloaded into the tube prior to insertion, and may then be deployed into the stomach S after the tube is inserted. - A filling tube may be removably coupled to the intragastric
obesity treatment implant 8 prior to insertion through the lubricated tube to facilitate filling theimplant 8 after implantation in the stomach S. For example, thefill valve 24 may comprise a slit valve that couples theballoon 10 to the filling tube. Thefill valve 24 may be a one way valve such that saline or another fluid may enter theballoon 10 via the filling tube, but the filling tube may then be removed after inflation of the intragastricobesity treatment implant 8 without a substantial amount of fluid being lost from theimplant 8. After inflation, the thin-walled tube and the filling tube may be removed from the patient, leaving theinflated implant 8 in the stomach S. - To remove the intragastric
obesity treatment implant 8 from the stomach, an aspirator may be fed down the patient's esophagus to puncture theimplant 8, releasing the saline or other fluid into the stomach S. The deflatedimplant 8 may then be removed from the stomach S via the esophagus using a grasper or other tool. In various embodiments, the intragastricobesity treatment implant 8 may be configured to be removed in other ways, for example, by passing out of the patient through digestion. - Turning now to
FIGS. 8-10 , an intragastricobesity treatment implant 28 will be discussed according to various embodiments of the present invention. Theimplant 28 is contained substantially within the patient's stomach S, and may be referred to as a stomach fluid transfer implant because it is configured to transfer stomach fluids between chambers or reservoirs to facilitate obesity control. For example, a pumpingchamber 40 may move stomach fluids or juices between one or more stimulation reservoirs, such areservoir 30. - Although various embodiments include one, two or more reservoirs (see, e.g., various configurations in
FIGS. 30A-30D ), it should be understood that any number of reservoirs may be utilized to facilitate obesity control without departing from the scope of the present invention. The intragastricobesity treatment implant 28 may be implanted in a similar manner as discussed above for other intragastric obesity treatment implants, for example, transorally, through the esophagus, and into the stomach, during a minimally invasive gastroendoscopic surgical procedure. - The intragastric
obesity treatment implant 28 may induce weight loss through a variety of methods. In an embodiment, the volume of theimplant 28 in the stomach S may reduce the total quantity of food ingested during a meal and reduce the sensation of pre-prandial hunger while implanted. In another embodiment, theimplant 28 may be configured to change shape or size when acted upon by the stomach S, for example, when acted upon byperistaltic motions 45 of the stomach S during digestion. Such changes may induce a changing sensation on the stomach S, and the changing sensation may be mechanotransduced by the stomach S to trigger the efferent nerves in the stomach S so as to encourage feelings of satiety. - In accordance with various embodiments, and with continued reference to
FIGS. 8-10 , the pumpingchamber 40 is coupled to anupper reservoir 30 via anupper tube 47 and to alower reservoir 32 via alower tube 48. Thetubing various reservoirs FIGS. 30A-30D ,reservoirs 330 may be connected bytubing 350 in series or in parallel with analternate pumping chamber 320. - With reference back to
FIGS. 8-10 , and in accordance with various embodiments, the pumpingchamber 40 moves fluid (e.g., gas, liquid, and combinations thereof) into thereservoirs chamber 40 moves any fluid (liquid or gas) that is inside of the stomach. Ahole 42 or plurality ofholes 42 is disposed in the walls of the pumpingchamber 40 to allow the stomach fluids to enter thepumping chamber 40. Thereservoirs chamber 40. In various embodiments, thereservoirs reservoirs 330 illustrated inFIGS. 30A-30D in accordance with various embodiments), or any other shape configured to allow fluid to enter and to exert appropriate pressure on the stomach S. - In an embodiment, when the stomach S is at rest between meals, and when the
peristaltic motions 45 are not occurring, theholes 42 in thepumping chamber 40 are open, which allows the stomach juices to enter thepumping chamber 40. Then, as theperistaltic motions 45 begin during digestion, theholes 42 are configured to be covered by the stomach S walls to prevent the stomach juices from exiting the pumpingchamber 40. In this manner, theperistaltic motions 45 compress thepumping chamber 40 and move the stomach juices from the pumpingchamber 40, through thetubes reservoirs FIG. 8B is illustrative of theperistaltic motions 45 and the resulting compression of the pumpingchamber 40. WhileFIG. 8B may appear to not show coverage of theholes 42 during theperistaltic motions 45, it should be understood that theholes 42 are covered by the stomach S walls during the compression process. After theperistaltic motions 45 stop, the stomach S relaxes, theholes 42 are uncovered, and more stomach juices enter thepumping chamber 40. - To regulate the flow of the fluids, and in accordance with various embodiments,
valves reservoirs tubing valves reservoirs chamber 40, but not from thereservoirs chamber 40. In various embodiments, as illustrated inFIGS. 8-10 and 14A-14B , thevalves FIGS. 15A-15B , aball check valve 60 may be utilized as a one-way valve. Other valves may be utilized to appropriately control the flow of fluid without departing from the scope of the present invention. As illustrated inFIGS. 8-10 , various embodiments include one-way valves reservoirs pumping chamber 40 and/or in thetubing - As noted above, in various embodiments, the
reservoirs reservoirs valve reservoirs reservoirs reservoirs valves release valves chamber 40 or otherwise utilized by the patient's body. - In an embodiment, a
flow restrictor reservoirs reservoirs chamber 40 ceases, the size/pressure of thereservoirs - With reference to
FIGS. 11A-11C , in an embodiment, a burst or burpvalve 36 may be utilized as a release mechanism. For example, theburp valve 36 may be configured to open when thereservoir 30 has been stretched to a certain degree, or when a specific strain has been induced in thereservoir 30. In this manner, once theburp valve 36 opens, it may remain open until thereservoir 30 returns to a nominal size/pressure. Other release mechanisms such as pressure relief valves which crack or open at a certain pressure may similarly be used to regulate the size of thereservoir 30 or the amount of fluid in thereservoir 30. - With reference now to
FIGS. 12-13 , the pumpingchamber 40 may be advantageously configured to be biased toward an open/expanded state. For example, the pumpingchamber 40 may want to return to its largest state after theperistaltic motions 45 cease and the stomach S relaxes. - In an embodiment, as illustrated in
FIGS. 12A-12B , a supporting structure, such as achamber tube 50 may be disposed within the pumpingchamber 40 to cause thepumping chamber 40 to return to its expanded state after theperistaltic motions 45 cease. A plurality of chamber tube holes 52 may be disposed in thechamber tube 50 to allow the stomach fluids to enter thechamber tube 50 and then pass through thetubes reservoirs 30, 32 (see, e.g.,FIGS. 8-10 ) during the pumping process. - In another embodiment, and with reference to
FIGS. 13A-13B , an open-celled foam 56 may be disposed within the pumpingchamber 40 to facilitate returning thepumping chamber 40 to its expanded state after pumping (e.g., after theperistaltic motions 45 cease). In such an embodiment, thetube 47 may be directly coupled to thepumping chamber 40, and thechamber tube 50 may not be utilized. However, achamber tube 50 may be employed in conjunction with the open-celled foam 56. In other embodiments, the walls of the pumpingchamber 40 may be sufficiently thick that they will cause thepumping chamber 40 to be biased toward its expanded state without the use of the open-celled foam 56 or thechamber tube 50. It should be understood that various combinations of these and other components may be utilized to cause thepumping chamber 40 to return to its expanded state after theperistaltic motions 45 cease. -
FIG. 16 illustrates an alternative tri-balloon intragastricobesity treatment implant 70 implanted in a stomach, whileFIGS. 17A-17B illustrate details of the implant. Theimplant 70 comprises a system of three balloons; a largercentral balloon 72, a smallerupper end balloon 74, and a smallerlower end balloon 76. The threeballoons tubular communication channel 78. The largercentral balloon 72 preferably has a fixed volume, while the twoend balloons communication channel 78. Theupper end balloon 74 further includes afill valve 80 which is used to inflate the two end balloons. Although not shown, a fill valve is also provided for the central fixedvolume balloon 72. - The larger
central balloon 72 occupies space in the stomach and presses against the stomach walls to properly position the end balloons 74, 76. Desirably, the smallerupper end balloon 74 maintains contact with the cardia region for stimulation. Fluid transfer between the twoend balloon communication channel 78. Arelief valve 82 on thecommunication channel 78 and within the chamber of thecentral balloon 72 ensures that theend balloon - The three
balloons central balloon 72 shown as slightly offset with a prolate spheroid shape. Thecentral balloon 72 is desirably wider about its equatorial diameter than the dimension along the axis defined by thecommunication channel 78. - In accordance with further embodiments of the present invention, and with reference to
FIGS. 18 and 19A/19B , an intragastricobesity treatment implant 100 with fluidly-connected active balloon reservoirs comprises a gastrointestinal implant with two lobes and/orballoon reservoirs balloon reservoirs obesity treatment implant 100 is similar to the implant 400 discussed above with reference toFIGS. 1-5 . - The intragastric
obesity treatment implant 100 may be configured to be implanted in the patient's stomach S, transorally, without invasive surgery, and without associated patient risks of invasive surgery. Recovery time is minimal because of reduced tissue healing post implantation. In one embodiment, theimplant 100 has a product life span in the stomach S of up to one year or longer. As will be discussed, theimplant 100 facilitates weight loss and obesity treatment through adipose trimming and/or fat reduction due to the patient consuming less food. - The intragastric
obesity treatment implant 100 comprises theballoon reservoirs implant 100 is configured to span the upper and lower stomach regions, ranging from the antrum to the cardia. - In addition to occupying space in the stomach S, the intragastric
obesity treatment implant 100 actively facilitates obesity treatment through early inducement of feelings of satiety and resulting reduced food consumption. For example, in one embodiment, a fluid disposed in theballoon reservoirs lumen connecting tether 114 that couples theupper reservoir 110 to thelower reservoir 112. As seen inFIG. 19B , the connectingtether 114 comprises a smallfluid transfer passageway 116 that allows the fluid to pass between thereservoirs - After ingestion of food by the patient, peristaltic digestive "churning" of the stomach S begins. These peristaltic motions cause various portions of the stomach S to repeatedly contract and relax to move food through the stomach S. Based on the geometry of the stomach S and the intragastric
obesity treatment implant 100, the peristaltic motions near the lower reservoir 112 (disposed near the antrum) may cause the stomach S to squeeze the reservoir. As thelower reservoir 112 is squeezed, fluid passes from it, through thefluid transfer passageway 116, and into the upper reservoir 110 (disposed adjacent the cardia). Theupper reservoir 110 preferably comprises a compliant material, such that the increased amount of fluid in thereservoir 110 causes it to expand and exert increased pressure on the cardia. This increased pressure on the cardia may induce early feelings of satiety by triggering the brain to release satiety-inducing hormones, so eating will likely cease, thus promoting weight loss over time. - In accordance with various embodiments, after digestion, the peristaltic motions in the stomach cease, resulting in reduced pressure exerted on the
lower reservoir 112. This reduced pressure exerted on thelower reservoir 112, in conjunction with the increased pressure in theupper reservoir 110 from the increased amount of fluid therein (and due to forces induced in the expanded compliant material in thereservoir 110 from expansion), causes the fluid in theupper reservoir 110 to return to thelower reservoir 112 via thefluid transfer passageway 116 until the pressure is substantially equalized between the two reservoirs. - As fluid transfers between the
reservoirs implant 100 alters to encourage a varied stimulus on the stomach. Changing the character of the stimulus on the stomach walls is believed not only to encourage feelings of satiety, but also to help prevent the stomach muscles from "learning" a particular stimulus and adapting to it. - The system desirably delays return flow from the
upper reservoir 110 to thelower reservoir 112 to maintain an expanded size of theupper reservoir 110 for a longer period of time. For example, thefluid transfer passageway 116 in the connectingtether 114 may be advantageously configured to have a small diameter to allow for a desired low flow rate. In one embodiment, thepassageway 116 has a diameter of approximately one millimeter. In another embodiment, a center band (not shown) (e.g., a rubber band) disposed around the connectingtether 114 appropriately reduces the size of thepassageway 116 to allow for a desired low flow rate. Other devices such as valves, flow restrictors, pressure reducers and the like and combinations thereof may be utilized to allow for a desired flow rate between thereservoirs - As seen in
FIG. 19B , the dual-lumen tether 114 also includes adeflation lumen 118 extending between thereservoirs passageway 116. Thedeflation lumen 118 is larger than thepassageway 116, and is only accessed to evacuate fluid from thereservoirs larger deflation lumen 118 is fitted on both sides with one-way valves 120 (e.g., duckbill valves as shown) which are oriented in opposite directions. Thevalves 120 prevent fluid flow from thedeflation lumen 118 into each reservoir, and therefore prevent flow from one reservoir to another through thedeflation lumen 118. The orientation of thevalves 120 is such that they will open if a vacuum (predetermined pressure differential across the valves) is introduced through avacuum port 122. For example, an instrument introduced trans-orally through the esophagus may be used to access thevacuum port 122 and pull fluid therefrom. The relatively large size of thedeflation lumen 118 and uninhibited flow through thevalves 120 encourages rapid deflation of theballoon reservoirs - The
tether 114 is rigid enough so that the dual lumens do not collapse or kink under various operating conditions. However, thetether 114 remains flexible enough such that the device as a whole can roughly orient itself inside a variety of stomach geometries. Indeed, the intragastricobesity treatment implant 100 in one embodiment is symmetric across theballoon reservoirs reservoir 112 is now the upper reservoir. One solution is to provide a reinforcing coil embedded within a moreflexible tether 114. Thetether 114 and all of its integral components may be manufactured from materials including, but not limited to, rubbers, fluorosilicones, fluoroelastomers, thermoplastic elastomers, or any combinations thereof, while a reinforcing coil may be formed of those materials as well as flexible metals such as Nitinol. -
FIG. 20 shows another dual-balloon intragastricobesity treatment implant 130 with a larger upper cardia-stimulatingballoon 132 fluidly-connected via relativelystiff tube 134 to asmaller positioning balloon 136. With reference also toFIGS. 21A-21B , thetube 134 includes a plurality of apertures (not shown) along its length within each of theballoons balloons way fill valve balloons balloons - The
larger balloon 132 has an inflated volume at least twice as big, and preferably at least three times as big, as thesmaller balloon 136 and is shaped to conform to the relatively larger cardia region within the stomach. Thesmaller balloon 136 has an inflated size large enough to prevent passing through the pylorus, but large enough to provide an atraumatic surface in contact with the antrum region in the lower region of the stomach. Thestiff tube 134 ensures that thelarger balloon 132 maintains contact with the cardia, stimulating upper baroreceptors. -
FIGS. 22A and 22B show an intragastricobesity treatment implant 150 in a patient's stomach S in two different configurations. Theimplant 150 comprises a largecentral pumping chamber 152 fluidly connected between twosmaller reservoirs 154 on either end. InFIG. 22A thecentral pumping chamber 152 is expanded to fill a substantial portion of the interior of the stomach S, while inFIG. 22B the pumping chamber has been compressed such that an outside fluid is transferred to theend reservoirs 154. In one embodiment, thepumping chamber 152 has a capacity of at least about 400 ml of saline, preferably between about 400-600 ml of saline, while the combined capacity of thesmaller reservoirs 154 is also at least about 400 ml. The intragastricobesity treatment implant 150 is similar in many respects to theimplant 28 discussed above with reference toFIGS. 8-10 , where, however, in contrast, a pumpingchamber 40 moves stomach fluids or juices betweenstimulation reservoirs 30. -
FIGS. 23 and 24 illustrate internal components of the intragastricobesity treatment implant 150, specifically between the pumpingchamber 152 and thereservoirs 154 on either end. As seen in the detail ofFIG. 24 , aconnector 156 between thechamber 152 and eachreservoir 154 includes alarge flow lumen 158 housing a one-way valve 160, and asmaller lumen 162 acting as a fluid transfer channel and providing flow restriction between the pumping chamber and each reservoir. Theconnector 156 comprises a substantially tubularmale member 170 within which is formed thelumens flange 172 that contacts an interior wall of therespective end reservoir 154. A portion of the tubularmale member 170 extending within the interior of thepumping chamber 152 includes external threading for mating with internal threading on anut 176. Thenut 176 tightens along themale member 170 and forces awasher 178 against an interior wall of thepumping chamber 152. Both thewasher 178 and theflange 172 of themale member 170 include concentric circular ribs that engage across the walls of thepumping chamber 152 andreservoir 154 and help prevent slipping of the assembly. - Desirably, the portion of the
male member 170 within theend reservoirs 154 is shaped to allow for easy handling, and in particular for applying torque, through adeflated end reservoir 154. For instance, themale member 170 within theend reservoirs 154 has a hexagonal, square or winged shape. An aperture in the side wall of thepumping chamber 152 that receives afill valve 180 permits introduction of thenuts 176 andwashers 178, and also provides access for a tool for either holding or turning the nut during assembly. - Once situated within the stomach S, the physician inflates the
implant 150 through thevalve 180 located along one side of thecentral pumping chamber 152. After food is ingested, the stomach's peristaltic forces act on thelarger pumping chamber 152 and squeeze fluid through thefluid transfer lumens 162 of theconnectors 156, and into theend reservoirs 154, as depicted inFIG. 22B . Theend reservoirs 154 thus inflate and stimulate the stomach walls. The increased pressure within theinflated end reservoirs 154 creates a pressure differential across theconnector 156, thus initiating a return flow from each reservoir back to thecentral pumping chamber 152. Additionally, an open-celled foam (such as that shown inFIGS. 13A-13B ) may be disposed within thepumping chamber 152 to facilitate returning it to its expanded state after pumping (e.g., after the peristaltic motions cease). In other embodiments, the walls of thepumping chamber 152 may be sufficiently thick that they will cause it to be biased toward its expanded state without the use of the open-celled foam. It should be understood that various combinations of these and other components may be utilized to cause thepumping chamber 152 to return to its expanded state after the peristaltic motions cease. - Because of the relatively small size of the
fluid transfer lumens 162, reverse flow of fluid from theend reservoirs 154 to thecentral pumping chamber 152 takes an extended period of time, preferably greater than two minutes and potentially up to several (e.g., two) hours. One desired low flow rate is about 1-20 ml/s. Preferably, a single set of stomach contractions are sufficient to create the geometry shown inFIG. 22B , which is believed to stimulate the inner walls of the stomach and induce satiety more than the relaxed geometry ofFIG. 22A . - In accordance with further embodiments of the present invention, and with reference to
FIGS. 25A-25B , an intragastricobesity treatment implant 200, such as a dual balloon gastrointestinal implant includes two lobes and/orballoons balloons balloons obesity treatment implant 200 describes a somewhat dog-bone shape, with identical lower andupper balloons implant 200 is strengthened to prevent kinking by virtue of its relative size and a central partition, as will be explained. Theimplant 200 is configured to span the upper and lower stomach regions, as shown inFIG. 25A , with thelower balloon 210 adjacent the antrum and theupper balloon 212 adjacent the cardia. - The
balloons obesity treatment implant 200 comprises twoidentical balloons partition 214. As seen inFIG. 25B , thepartition 214 desirably comprises the juxtaposed flat inner end walls of the twoballoons balloon tubular portion bulbous end portions end portions ridges 224 around their circumference between which are grooves, best seen inFIG. 25A . - As will be discussed, the intragastric
obesity treatment implant 200 facilitates weight loss and obesity treatment by taking up space within the stomach as well as by stimulating satiety-inducing nerves. Theimplant 200 occupies space inside the stomach S, thereby decreasing the amount of food that is ingestible by the patient, which may result in weight loss. The flutes orridges 224 and accompanying grooves prevent obstruction of food as it moves through the pylorus and into the duodenum of the patient. Namely, food passes by theimplant 200 through the grooves between theflutes 224 and along the stomach S walls. - The intragastric
obesity treatment implant 200 further actively treats obesity through early inducement of feelings of satiety and resulting reduced food consumption. For example, in one embodiment, fluid such as saline may move between theballoons FIG. 25B ) that separates the inner chambers of theballoons center partition 214 includes aduckbill valve 226 and parallel fluid passageways (not shown) that allow fluid to pass between theballoons duckbill valve 226 permits fluid to flow from thelower balloon 210 to theupper balloon 212 but prevents a reverse flow. One or more fluid passageways near or surrounding thevalve 226 permit fluid flow back from theupper balloon 212 to thelower balloon 210. The flow orifice through theduckbill valve 226 is larger than the combined area of the return passageway(s), and thus fluid may flow at a greater rate from thelower balloon 210 to theupper balloon 212. - After ingestion of food by the patient, random peristaltic digestive "churning" of the stomach S begins. These peristaltic motions cause various portions of the stomach S to repeatedly contract and relax to move food through the stomach S. Based on the geometry of the stomach S and the intragastric
obesity treatment implant 200, the peristaltic motions near the lower balloon 212 (disposed near the antrum) may cause the stomach S to squeeze theballoon 212. As thelower balloon 212 is squeezed, fluid passes rapidly through thevalve 226 in thecenter partition 214, and into the upper balloon 210 (disposed adjacent the cardia). Theupper balloon 210 desirably comprises a compliant material, such that the increased amount of fluid in theballoon 210 causes theballoon 210 to expand and exert increased pressure on the cardia. This increased pressure on the cardia may induce early feelings of satiety by triggering the brain to release satiety-inducing hormones, so eating will likely cease, thus contributing to eventual weight loss. - In accordance with various embodiments, after digestion, the peristaltic motions in the stomach cease, resulting in reduced pressure exerted on the
lower balloon 212. This reduced pressure, in conjunction with the increased pressure in theupper balloon 210 from the increased amount of fluid therein (and due to forces induced in the expanded compliant material in theballoon 210 from expansion), causes the fluid to return to thelower balloon 212 via the fluid passageway(s) in thecenter partition 214 until the pressure is substantially equalized between the twoballoons - The return flow to the
lower balloon 212 may be inhibited to maintain an expanded size of theupper balloon 210 for a longer period of time. For example, the passageway(s) in thecenter partition 214 preferably has a maximum size to allow for a desired low flow rate. In one embodiment, the passageway may be a through hole having a diameter of approximately 1 mm. Stated another way, the maximum flow rate from thelower balloon 212 to theupper balloon 210 is desirably substantially greater than in the reverse direction. For example, theduckbill valve 226 enables twice the flow rate from thelower balloon 212 to theupper balloon 210 than the reverse flow through the return passageway(s). In one specific example, the entire intragastricobesity treatment implant 200 has a fluid capacity of about 500 ml which is typically split evenly (250-250) between the two balloon chambers when the pressures in both are equal. Up to 200 ml of the fluid in thelower balloon 212 chamber rapidly flows through thevalve 226 to theupper balloon 210 chamber from peristaltic contractions. This may take just a few seconds. Swelling of theupper balloon 210 applies pressure to the surrounding cardia and its subcutaneous nerves, thereby stimulating the brain's release of satiety-inducing hormones. Subsequently, the return fluid passageway(s) permit a trickle flow back to thelower balloon 212 chamber that takes at least 10 seconds, potentially minutes. - The intragastric
obesity treatment implant 200 is preferably implanted in the patient's stomach S transorally, without invasive surgery and its associated patient risks. Recovery time is minimized because of reduced tissue healing post implantation. In one embodiment, theimplant 200 may have a product life span in the stomach S of up to one year or longer. Theupper balloon 212 conveniently has afill valve 230 along the longitudinal axis at thebulbous end 222 to allow theimplant 210 to be filled with saline after implantation in the stomach S. By filling theupper balloon 212, such as by using a fill line pre-connected to a syringe, thelower balloon 210 is also filled by transfer through the fluid passageway(s) across thepartition 214. Thus, theimplant 200 may be disposed in the stomach S via the esophagus in a substantially non-inflated state. For example, a lubricated (e.g., Teflon), thin-walled tube (not shown) may be inserted through the patient's mouth, down the esophagus, and partially into the stomach S. Theimplant 200 is preloaded in a non-inflated and compressed state into the tube prior to insertion, and then expelled into the stomach S from the distal end of the tube. A fluid filling tube coupled to thefill valve 230 is removably coupled to the intragastricobesity treatment implant 200 prior to insertion through the lubricated tube to facilitate filling the implant after implantation. Thefill valve 230 is a one way valve such that the filling tube can be removed after inflation of theimplant 200 without a substantial amount of fluid being lost. - In a preferred embodiment, the intragastric
obesity treatment implant 200 features a rapid deflation valve 232 located approximately at the center of the implant which can deflate both chambers of theballoons nipple 234 opening to the exterior of the implant and in fluid communication with a pair of one-way valves 236 extending in opposite directions into each of the dual fluid chambers of the implant. The one-way valves 236 permit flow from the dual chambers and out of thenipple 234, but prevent flow in the opposite direction. At the time that the implant will be removed, a "lasso" device (not shown) with a slip-knotted cord is used to capture the intragastricobesity treatment implant 200 about its midsection. The sideways-orientednipple 234 may then be accessed using a wire-stiffened fluid removal line or aspirator having an end specially configured to engage the nipple (e.g., with a single-barbed end). Once engaged, the fluid removal line exerts a vacuum pressure on the two one-way valves 236 to evacuate the inside of both balloon chambers simultaneously. The vacuum may be created using an empty syringe connected to the fluid line. - Alternatively, a standard endoluminal cutter maybe deployed down an overtube through the esophagus to cut each balloon chamber in one or more places so the saline therein can drain into the stomach cavity. Once the
balloons obesity treatment implant 200 may be configured to be removed in other ways, for example, by passing out of the patient through digestion. -
FIG. 26A shows an alternative dual-balloon intragastricobesity treatment implant 250 similar to that inFIGS. 25A-25B but with a more uniform longitudinal shape. Specifically, theimplant 250 includes alower balloon 252 connected to anupper balloon 254 at a centraldiametric partition 256. The twoballoons longitudinal flutes 260 which match up to provide uniform longitudinal flutes and intermediate grooves along the entire length of theimplant 250. Although not shown, theimplant 250 desirably features a fill valve on one end, a one-way fluid transfer valve as well as return fluid passageways in thepartition 256, and a rapid deflation valve, like the embodiment ofFIGS. 25A-25B . - Once implanted in the stomach S, peristaltic contractions may squeeze the
lower balloon 252 as shown inFIG. 26B . This causes fluid transfer through the one-way valve in thepartition 256, which rapidly fills theupper balloon 254. The asymmetric shape created contacts the inner walls of the cardia in the upper end of the stomach and stimulates satiety-inducing nerves. Moreover, the presence of the filled intragastricobesity treatment implant 250 takes up space within the stomach S, though the deep grooves between theflutes 260 help food bypass the implant. -
FIGS. 27-29 illustrate a still further inflatable intragastricobesity treatment implant 270 having an outer saline-filled chamber and an inner air-filled chamber. The exterior shape of theimplant 270 is similar to the embodiment shown inFIGS. 26A-26B , with a firstexterior balloon 272 connected at one end in series to a secondidentical exterior balloon 274 at apartition wall 276. The twoballoons partition wall 276 extends diametrically perpendicular to the axis. Each of theballoons longitudinal flutes 278 creatinglongitudinal grooves 280 therebetween. The flat mating inner ends abut at the partition plane and the alternatingflutes 278 andgrooves 280 line up to form the elongated somewhat oval-shaped configuration. The intragastricobesity treatment implant 270 features a convenientouter fill valve 282 centrally located on the outer end of thesecond balloon 274. - As seen in
FIG. 27 , the intragastricobesity treatment implant 270 has a configuration much like that shown inFIGS. 26A-26B , and indeed functions much like that earlier embodiment. In particular, theimplant 270 may be deflated for transoral insertion into the stomach through the esophagus using a lubricated overtube, and then filled. Once in the stomach, theimplant 270 takes up space and also actively changes shape in reaction to peristaltic contractions. Specifically, fluid may be transferred between the twoballoons outer flutes 278 contact the stomach wall and channels defined by thegrooves 280 therebetween permit food to flow past the implant. - In contrast to the earlier embodiment, however, the intragastric
obesity treatment implant 270 features a concentric balloon structure with dual saline-filled outer balloons surrounding an air-filled core balloon that occupies volume within the outer balloons. With reference to the longitudinal sectional view ofFIG. 28 , the connectedouter balloons diametric partition 276 therebetween are shown surrounding an inner air-filledcore balloon 284. Thecore balloon 284 includes an upper portion formed as amonolithic bladder 286 residing entirely within the chamber of the firstouter balloon 272, and a lower portion comprising a series of elongated longitudinally-orientedbladders 288. Theelongated bladders 288 are each fluidly connected to the singlemonolithic bladder 286 and extend across thepartition 276 into the chamber of the secondouter balloon 274. It should be noted that the air-filledcore balloon 284 may be located within a single outer saline-filled outer balloon in a manner that orients the outer balloon, though the partitioned dual outer balloon provide additional advantages - The
partition 276 provides sealed apertures for passage of each of theelongated bladders 288 without compromising the fluid separation between the chambers of the first and secondouter balloons partition 276 includes aduckbill valve 290 and parallel fluid passageways (not shown) that allow fluid to pass back and forth between theballoons duckbill valve 290 permits fluid to flow from the first orlower balloon 272 to the second orupper balloon 274 but prevents reverse flow. One or more fluid passageways near or surrounding thevalve 290 permit fluid flow back from thesecond balloon 274 to thefirst balloon 272. The flow orifice through theduckbill valve 290 is larger than the combined area of the return passageway(s), and thus fluid may flow at a greater rate from thefirst balloon 272 to thesecond balloon 274. As before, the firstouter balloon 272 desirably resides below the secondouter balloon 274 in the stomach such that theouter fill valve 282 is located on the proximal end (or toward the esophagus) of the intragastricobesity treatment implant 270. - With reference still to
FIG. 28 , theouter fill valve 282 has anoutlet aperture 294 projecting into the secondouter balloon 274 and toward an inner fill valve in the corresponding end of thecore balloon 284. As will be described below, a single fill tube may be used to inflate both theinner core balloon 284 with air, and the outerdual balloons - The
core balloon 284 has a single fluidly-connected chamber and remains filled with air throughout use of the implant. In contrast, the twoouter balloons partition 276 over the implant duration, as was described above. More particularly, fluid rapidly passes through the one-way valve 290 from the chamber of the firstouter balloon 272 to the chamber of the secondouter balloon 274, and then returns more slowly through the surrounding fluid passageway(s). Since themonolithic bladder 286 of the upper portion has a larger volume than the combined volumes of theelongated bladders 288 of the lower portion of the air-filledballoon 284, the intragastricobesity treatment implant 270 has greater buoyancy toward the end of the secondouter balloon 274 having thefill valve 282. As a consequence, the end with thefill valve 282 remains oriented upwards toward the cardia by virtue of its greater buoyancy. Moreover, as the firstouter balloon 272 tends to be squeezed more forcefully by contractions of the lower stomach at the antrum, some of the air residing in theelongated bladders 288 may be forced across thepartition 276 into the chamber of the secondouter balloon 274, further contributing to the buoyancy differential across the partition. All this results in the end having the secondouter balloon 274 floating and remaining in the top of the stomach adjacent the cardia. Because thefill valve 282 permits more rapid fluid transfer to the chamber of the secondouter balloon 274, this end tends to swell to a greater extent and contact the surrounding cardia, thus stimulating the subcutaneous nerves and contributing to a sensation of being full. -
FIGS. 29A and 29B illustrate two stages in filling the intragastricobesity treatment implant 270. First, an obturator 1600 advances through an overtube 1602 that passes through the esophagus. The distal end of the obturator 1600 has a tapered shape which easily engages and penetrates a central outer opening of thefill valve 282.FIG. 29A illustrates the first, air-filling position, with the tip of the obturator 1600 engaged in the inner valve that is sealed to only the air balloon.FIG. 29B shows the obturator tube still in place, but the lumen tip is now pulled back slightly, so it "pops" into the second, (outer) valve. - The operator advances the obturator 1600 until a distal enlarged tip 1604 pops into a similarly-shaped cavity (not numbered) within the
fill valve 282, as seen inFIG. 29A . In this position, the open end of the obturator 1600 lumen fluidly communicates with anoutlet 292 of the inner fill valve that opens to the interior of thecore balloon 284. The technician then inflates thecore balloon 284 with air. Subsequently, the technician retracts the obturator 1600 a short distance into the position shown inFIG. 29B , wherein the distal enlarged tip 1604 pops into another mating cavity within theouter fill valve 282. At this location, the open end of the obturator 1600 fluidly communicates with thefill valve outlet 294 that opens to the interior of the secondouter balloon 274. The technician can then fill the secondouter balloon 274 with saline, which gradually migrates to the chamber of the firstouter balloon 272 through the fluid passageway(s) in thepartition 276. With this configuration, the concentric air/saline balloons may be filled using one fill tube in a sequential procedure. -
FIGS. 30A-30D schematically illustrate various configurations ofreservoirs 330 in the shape of simple spheres connected bytubing 350, in series or in parallel, and with apumping chamber 320. Various numbers and/or configurations ofreservoirs 330 andtubing 350 are contemplated within the scope of the present invention. For instance, onepumping chamber 320 in series with asingle reservoir 330 is shown inFIGS. 30A and 30D . Onepumping chamber 320 in the middle ofmultiple reservoirs 330 is shown inFIG. 30B , while apumping chamber 320 connected to one of a loop ofreservoirs 330 is seen inFIG. 30C . - While not shown, the outer surface of the intragastric implants disclosed herein may further include additional uneven surface features such as small rounded bumps or protrusions, quill-like extensions, dimples or recesses, and the like. These features, upon contact with the inner stomach wall of the patient may further trigger hormone release or otherwise aid the patient in feeling full. Such features may be particularly effective for those embodiments which stimulate the cardia. The examples in
FIGS. 31-33 may be applied to any of the various implants and surfaces disclosed herein. - For instance,
FIG. 31 illustrates a sphericalintragastric implant 510 having numerous external protrusions orbumps 512 projecting outward therefrom. Thesebumps 512 separately contact the inner walls of the stomach, potentially increasing the stimulation to the surrounding satiety-sensing nerves. As shown, a plurality ofbumps 512 may be equally spaced apart on the outer surface and interspersed with flat portions. In one embodiment, thebumps 512 may be of equal heights and diameters, or they may be configured to have different heights and/or diameters. For example, havingbumps 512 with different heights and/or diameters may be advantageous for preventing the stomach from adjusting to the bumps. Thebumps 512 separately contact the inner walls of the stomach, potentially increasing the stimulation to the surrounding satiety-sensing nerves. - Another example of exterior stimulation features is seen in
FIG. 32 , where anintragastric implant 520 formed as a sphere features a multitude of small flagella or quill-like extensions 522 extending outward therefrom. As shown, a plurality ofextensions 522 may be equally spaced apart. In one embodiment, theextensions 522 may be of equal heights and diameters, or they may be configured to have different heights and/or diameters. In one embodiment, theextensions 522 may be extremely flexible and may bend when a pressure is exerted on them from the inner stomach wall of the patient. Alternatively, theextensions 522 may be stiffer and might not bend as much when a pressure is exerted on them from the inner stomach wall of the patient. In another embodiment, some of theextensions 522 may have a first flexibility while some of the extensions may have a second flexibility. -
FIG. 33 illustrates another example of uneven surface features on anintragastric implant 550. As shown, theintragastric implant 550 is a substantially spherical object with recesses ordimples 555 extending inward from the surface of theintragastric implant 550. In one embodiment, theintragastric implant 550 may be considered to have a surface comprised ofrecesses 555 andflat portions 560. As shown, a plurality ofrecesses 555 may be equally spaced apart on the outer surface. As shown, recesses 555 do not contact each other, and may be of equal heights and diameters. In addition to being depressed, therecesses 555 may employ a thinner wall. For example, if theflat portions 560 have a wall thickness of 20 millimeters, therecesses 555 may have a wall thickness of 10 millimeters. With a thinner wall, therecesses 555 may be more susceptible to larger strains. Theintragastric implant 550 is effectively triggered in the patient's stomach by stomach contractions. These stomach contractions increase the pressure in theintragastric implant 550. If onerecess 555 is not in contact with the stomach wall, it will deform outward until it comes into contact with the stomach wall. - It should be noted that the embodiments shown in
FIGS. 31-33 rotate freely within the stomach, and that thebumps 512, quill-like extensions 522, or recesses 555 may be provided in a non-uniform distribution so as to take advantage of the benefits of the rotational variation described above. That is, a regular array of such exterior features may stimulate the stomach wall more than a smooth surface, but also providing a non-uniform distribution will create different sensations on a constantly changing basis. - In accordance with various embodiments, the intragastric obesity treatment implants disclosed herein may be advantageously configured to utilize naturally occurring and/or transient stomach contractions to trigger a sustained change in the implant, which results in a physiological response that may in turn result in weight loss. It should be noted that the feeling of satiety induced by the stimulation mechanisms disclosed herein is often aligned with feeding, such that the patient may begin to associate the two events -- eating a meal and feeling sated.
- Various materials may be used to construct the components disclosed in the various embodiments herein, for example, rubbers, fluorosilicones, fluoroelastomers, thermoplastic elastomers, thermoplastics, thermosets, metals, glass, or any combinations thereof. It should also be understood that certain components may be removed or added without departing from the scope of the present invention.
- The implantable devices described herein will be subjected to clinical testing in humans. The devices are intended to treat obesity, which is variously defined by different medical authorities. In general, the terms "overweight" and "obese" are labels for ranges of weight that are greater than what is generally considered healthy for a given height. The terms also identify ranges of weight that have been shown to increase the likelihood of certain diseases and other health problems. Applicants propose implanting the devices as described herein into a clinical survey group of obese patients in order to monitor weight loss.
- In one study, clinical studies will utilize a dual-balloon implant similar to the intragastric
obesity treatment implant 100 described above with reference toFigures 18-19 and in conjunction with the following parameters. - Silicone materials used include 3206 silicone for any shells, inflatable structures, or otherwise flexible hollow structures. Any fill valves will be made from 4850 silicone with 6% BaSo4. Tubular structures or other flexible conduits will be made from silicone rubber as defined by the Food and Drug Administration (FDA) in the Code of Federal Regulations (CFR) Title 21 Section 177.2600.
- Total length of implant 100 - between 10-26 cm (4-10 inch), preferably 12 cm (4.75 inch)
- Diameters of upper and
lower reservoirs reservoir 110, 112 - 5-13 cm (2-5 inch), preferably 5 cm (2 inch) - OD of connecting tether 114 - 3-13 mm (0.125-0.50 inch), preferably 9 mm (0.36 inch)
- the devices are for human implant,
the devices are intended to occupy gastric space while also applying intermittent pressure to various and continually changing areas of the stomach;
the devices are intended to stimulate feelings of satiety, thereby functioning as a treatment for obesity. - The device is intended to be implanted transorally via endoscope into the corpus of the stomach.
- Implantation of the medical devices will occur via endoscopy.
- Nasal/Respiratory administration of oxygen and isoflurane to be used during surgical procedures to maintain anesthesia as necessary.
- When deployed this device will occupy space in the caudal aspect of the corpus and in portions of the rostral corpus or antrum. The device is non-fixating and will be inflated using isotonic saline. The image below is an appropriately scaled rendering of the device in its deployed state.
- One exemplary implant procedure is listed below.
- a. Perform preliminary endoscopy on the patient to examine the GI tract and determine if there are any anatomical anomalies which may affect the procedure and/or outcome of the study.
- b. Insert and introducer into the over-tube.
- c. Insert a gastroscope through the introducer inlet until the flexible portion of the gastroscope is fully exited the distal end of the introducer.
- d. Leading under endoscopic vision, gently navigate the gastroscope, followed by the introducer/over-tube, into the stomach.
- e. Remove gastroscope and introducer while keeping the over-tube in place.
- f. OPTIONAL: Place the insufflation cap on the over-tubes inlet, insert the gastroscope, and navigate back to the stomach cavity.
- g. OPTIONAL: Insufflate the stomach with air/inert gas to provide greater endoscopic visual working volume.
- h. Fold the Dual-Balloon implant (similar to a balloon catheter) and insert the lubricated implant into the over-tube, with inflation catheter following.
- i. Under endoscopic vision, push the Dual-Balloon implant down the over-tube with gastroscope until visual confirmation of deployment of the device into the stomach can be determined.
- j. Remove the guide-wire from the inflation catheter is used.
- k. Inflate the implant using a standard BioEnterics Intragastric Balloon System ("BIB System") Fill kit. NOTE: Table 2 illustrates the relative inflation volumes associated with the various scaled implants appropriately selected at the time of implant.
- l. Using 50-60cc increments, inflate the volume to the desired fill volume.
- m. Remove the inflation catheter via over-tube.
- n. Inspect the Dual-Balloon implant under endoscopic vision for valve leakage, and any other potential anomalies. Record all observations.
- o. Remove the gastroscope from over-tube.
- p. Remove the over-tube from the patient.
-
- Weight Loss
- Comprehensive Metabolic Panel (CMP)
- HbAlC
- Lipid Panel
- Tissue Samples/Response
- Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
- Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
- The terms "a," "an," "the" and similar referents used in the context of describing the invention(especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
- Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
- Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
- Furthermore, references may have been made to patents and printed publications in this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
- Specific embodiments disclosed herein may be further limited in the claims using "consisting of" or "consisting essentially of" language. When used in the claims, whether as filed or added per amendment, the transition term "consisting of" excludes any element, step, or ingredient not specified in the claims. The transition term "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.
- In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
-
- 1. An intragastric obesity treatment implant, comprising:
- an outer inflatable balloon configured to be disposed in a patient's stomach, wherein the outer inflatable balloon is configured to be inflated with saline after implantation in the patient's stomach and having a length oriented along a longitudinal axis that substantially spans the stomach such that a first end of the implant is positioned adjacent the antrum and a second end of the implant is positioned adjacent the cardia; and
- a core balloon located within the outer inflatable balloon is adapted to contain air without leaking so as to occupy volume within the outer inflatable balloon, wherein the core balloon includes an upper portion residing within the second end of the outer balloon, and a lower portion residing within the first end of the outer balloon having a smaller internal volume than the upper portion such that the greater buoyancy of the upper portion tends to orient the second end of the outer balloon at the top of the stomach cavity adjacent the cardia.
- 2. The implant of
item 1, wherein the upper portion is formed as a monolithic bladder and the lower portion of the core balloon comprises a series of elongated longitudinally-oriented bladders fluidly connected to the single monolithic bladder. - 3. The implant of
item 1, wherein the outer inflatable balloon includes first and second inflatable balloons respectively defining the first and second ends of the implant and separated from each other by a one-way valve and a series of fluid passageways, the one-way valve permitting fluid flow of a predetermined maximum rate from the first inflatable balloon to the second inflatable balloon and the fluid passageways permitting fluid flow in the opposite direction from the second inflatable balloon to the first inflatable balloon at a rate less than the predetermined maximum rate, wherein in response to peristaltic inward pressure from the stomach proximate the first inflatable balloon, a portion of the fluid moves from the first inflatable balloon through the one-way valve into the second inflatable balloon and causes the second inflatable balloon to expand to exert pressure on the cardia and induce a feeling of satiety in the patient. - 4. The implant of
item 1, wherein each of the first and second inflatable balloons includes an inner end wall diametrically-oriented with respect to the longitudinal axis, the end walls being joined in abutting relationship to form a partition in the implant, and wherein the one-way valve and fluid passageways cross the partition. - 5. The implant of
item 1, wherein the core balloon spans the partition. - 6. The implant of
item 1, further including an outer fill valve in the outer inflatable balloon at the first end of the implant with an outlet aperture projecting within the outer inflatable balloon and toward an inner fill valve in the core balloon such that a single fill tube may be used to inflate both the inner core balloon with air and the outer inflatable balloon with saline.
Fill volume range of 400-700 mL (this is the fill range of a standard BioEnterics Intragastric Balloon System ("BIB System") per the directions for use), with a nominal fill of 550 mL. | ||
Device | Scaling - (% Relative to clinical BIB) | Max. Fill (cc) |
A | 50 | 275 |
| 60 | 330 |
| 70 | 385 |
Claims (15)
- An intragastric obesity treatment implant, comprising:a first inflatable balloon configured to be disposed in a patient's stomach, wherein the first inflatable balloon is configured to be inflated with a fluid after implantation in the patient's stomach;a second inflatable balloon fluidly coupled to the first inflatable balloon such that the inflatable balloons have a longitudinal length that substantially spans the stomach and the second inflatable balloon is positioned adjacent the cardia, wherein the second inflatable balloon is configured to be inflated with a fluid after implantation in the patient's stomach;a flow restrictor interposed between the first and second inflatable balloons and adapted to regulate flow therebetween, wherein in response to peristaltic inward pressure from the stomach proximate the first inflatable balloon, a portion of the fluid moves from the first inflatable balloon through the flow restrictor into the second inflatable balloon and causes the second inflatable balloon to expand to exert pressure on the cardia and induce a feeling of satiety in the patient.
- The implant of claim 1, wherein the first inflatable balloon and the second inflatable balloon comprise a plurality of external grooves oriented along an axis connecting the two balloons and configured to allow ingested food to pass by so that the ingested food may be digested by the patient, optionally
wherein the first inflatable balloon comprises eight grooves, and wherein the second inflatable balloon comprises eight grooves. - The implant of claim 1, wherein the flow restrictor comprises a narrow portion connecting the first inflatable balloon and the second inflatable balloon, and further including an elastic band wrapped around the narrow portion.
- The implant of claim 1, wherein the flow restrictor comprises a narrow portion connecting the first inflatable balloon and the second inflatable balloon, and wherein the narrow portion includes fluted wings configured to provide structural support to the narrow portion.
- The implant of claim 1, further including a single evacuation valve that may be accessed with an aspirator to simultaneously evacuate both the first and second inflatable balloons.
- The implant of claim 1, wherein the implant has a dog-bone shape, with identical first and second inflatable balloons defining enlarged outer ends joined by a smaller middle portion.
- The implant of claim 1, wherein the first and second inflatable balloons each includes an inner end wall diametrically-oriented with respect to the longitudinal axis, the end walls being joined in abutting relationship to form a partition in the implant, and wherein the flow restrictor comprises fluid passageways across the partition.
- The implant of claim 7, further including a valve positioned in the partition that permits flow from the first inflatable balloon to the second inflatable balloon but prevents reverse flow therebetween, the valve having a flow rate capacity greater than the fluid passageways of the flow restrictor.
- The implant of claim 7, wherein the first and second inflatable balloons have a generally uniform longitudinal exterior shape.
- The implant of claim 1, wherein the second inflatable balloon is at least three times the volume of the first inflatable balloon.
- The implant of claim 1, wherein the combined volumes of the first and second inflatable balloons is at least about 400 ml of saline.
- The implant of claim 1, further including a tether having a first fluid passage fluidly connecting the first and second inflatable balloons and having the flow restrictor therein, optionally
wherein the first fluid passage has a size that permits a maximum flow rate of about 1-20 ml/s. - The implant of claim 12, wherein the tether includes two passages, the first fluid passage being open between the first and second inflatable balloons and a second passage having one-way flow valves therein at each end adjacent each of the first and second inflatable balloons that prevent fluid from traveling from the second passage into the respective first or second inflatable balloon but permit flow from the respective first or second inflatable balloon into the second passage upon a predetermined pressure differential thereacross.
- The implant of claim 1, further including a third inflatable balloon positioned between the first and second inflatable balloons, the third inflatable balloon having a fixed volume and not being freely fluidly connected to the first and second inflatable balloons, optionally
wherein the third inflatable balloon comprises a larger balloon than either of the first and second inflatable balloons, and wherein the first and second inflatable balloons fluidly communicate with each other via a communication tube extending through the third inflatable balloon. - The implant of claim 14, further including a relief valve on the communication tube and within the third inflatable balloon that opens from a threshold pressure from the connected first and second inflatable balloons to vent fluid into the third inflatable balloon.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39468510P | 2010-10-19 | 2010-10-19 | |
US39459210P | 2010-10-19 | 2010-10-19 | |
US201161478013P | 2011-04-21 | 2011-04-21 | |
EP11773972.2A EP2629711B1 (en) | 2010-10-19 | 2011-10-18 | Intragastric implants with multiple fluid chambers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11773972.2A Division EP2629711B1 (en) | 2010-10-19 | 2011-10-18 | Intragastric implants with multiple fluid chambers |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3023081A1 true EP3023081A1 (en) | 2016-05-25 |
Family
ID=44863273
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11773972.2A Not-in-force EP2629711B1 (en) | 2010-10-19 | 2011-10-18 | Intragastric implants with multiple fluid chambers |
EP15202671.2A Withdrawn EP3023081A1 (en) | 2010-10-19 | 2011-10-18 | Intragastric implants with multiple fluid chambers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11773972.2A Not-in-force EP2629711B1 (en) | 2010-10-19 | 2011-10-18 | Intragastric implants with multiple fluid chambers |
Country Status (4)
Country | Link |
---|---|
US (1) | US9498365B2 (en) |
EP (2) | EP2629711B1 (en) |
ES (1) | ES2562035T3 (en) |
WO (1) | WO2012054410A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4398244B2 (en) | 2001-10-04 | 2010-01-13 | ネオヴァスク メディカル リミテッド | Flow reduction implant |
US8100932B2 (en) * | 2009-03-31 | 2012-01-24 | Onciomed, Inc. | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
WO2014055766A1 (en) * | 2012-10-04 | 2014-04-10 | Apollo Endosurgery, Inc. | Intragastric balloon for treating obesity |
US10219931B2 (en) | 2011-11-09 | 2019-03-05 | Easynotes Ltd. | Obstruction device |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
WO2014040064A1 (en) * | 2012-09-10 | 2014-03-13 | Boston Scientific Scimed, Inc. | Catheter with releasable balloon and related methods |
US10137023B2 (en) | 2012-09-14 | 2018-11-27 | Medibotics Llc | Colonnade (TM) expandable intragastric food flow lumen device |
US9125660B2 (en) | 2013-04-14 | 2015-09-08 | Easynotes Ltd. | Inflation and deflation of obstruction device |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9358120B2 (en) | 2013-03-14 | 2016-06-07 | DePuy Synthes Products, Inc. | Expandable coil spinal implant |
US9585761B2 (en) | 2013-03-14 | 2017-03-07 | DePuy Synthes Products, Inc. | Angulated rings and bonded foils for use with balloons for fusion and dynamic stabilization |
US9572676B2 (en) * | 2013-03-14 | 2017-02-21 | DePuy Synthes Products, Inc. | Adjustable multi-volume balloon for spinal interventions |
CN103330608A (en) * | 2013-06-26 | 2013-10-02 | 汉斯·葛根森 | Air balloon device used for lightening body weight and symptoms |
EP3134010B1 (en) * | 2014-04-25 | 2020-04-22 | Flow Medtech, LLC | Left atrial appendage occlusion device |
EP3193790A4 (en) | 2014-09-19 | 2018-10-03 | Flow Medtech, Inc. | Left atrial appendage occlusion device delivery system |
US20170333049A1 (en) * | 2016-05-23 | 2017-11-23 | Easynotes Ltd. | Pyloric obstruction device with space-occupying device |
WO2019136227A1 (en) * | 2018-01-06 | 2019-07-11 | Barix Medical Corp., a Delaware Corporation | Simplified implantable gastric balloon system with self deflating timer |
WO2020076927A1 (en) * | 2018-10-09 | 2020-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Bariatric balloon systems |
CN109223272A (en) * | 2018-11-21 | 2019-01-18 | 郑州大学第附属医院 | Double balloon-systems and its application method in a kind of stomach |
KR102163651B1 (en) * | 2018-12-24 | 2020-10-08 | 박용희 | using buoy system for dirt |
CN113891686A (en) | 2019-01-23 | 2022-01-04 | 内奥瓦斯克医疗有限公司 | Flow-altering device with cover |
CN113332014A (en) * | 2020-02-18 | 2021-09-03 | 上海微创医疗器械(集团)有限公司 | Gastric balloon, gastric balloon structure and use method of gastric balloon structure |
EP4304527A1 (en) * | 2021-03-08 | 2024-01-17 | Poriferous, LLC | Sinus implant |
ES2933224B2 (en) | 2021-07-09 | 2023-12-12 | Servicio Cantabro De Salud | INTRAGASTRIC DEVICE |
CN114652490B (en) * | 2022-05-20 | 2022-09-02 | 茂名市人民医院 | Foldable artificial meniscus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084061A (en) | 1987-09-25 | 1992-01-28 | Gau Fred C | Intragastric balloon with improved valve locating means |
WO2006138480A1 (en) * | 2005-06-16 | 2006-12-28 | Hively Robert L | Gastric bariatric apparatus with selective inflation and safety features |
US20090149879A1 (en) * | 2007-12-10 | 2009-06-11 | Dillon Travis E | Dynamic volume displacement weight loss device |
WO2010087757A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | Obesity treatment |
Family Cites Families (255)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1702974A (en) | 1928-05-12 | 1929-02-19 | Spalding & Bros Ag | Collapsible valve and method of making same |
US2087604A (en) | 1935-02-25 | 1937-07-20 | Ira S Mosher | Hair clamp for permanent wave apparatus |
US2163048A (en) | 1937-02-13 | 1939-06-20 | Mckee Brothers Corp | Band clamp |
US2619138A (en) | 1949-10-07 | 1952-11-25 | Lee Marler Herod | Straight beam adjustable jaw cam clamp |
BE758322A (en) | 1969-11-03 | 1971-04-01 | Bosch Gmbh Robert | DEVICE FOR WIPING GLASSES SUCH AS HEADLIGHT GLASS AND REAR LAMP OF MOTOR VEHICLES |
US3719973A (en) | 1972-03-03 | 1973-03-13 | Might Mac Inc | T-bar zipper tab handle |
US3840018A (en) | 1973-01-31 | 1974-10-08 | M Heifetz | Clamp for occluding tubular conduits in the human body |
US3919724A (en) | 1974-06-07 | 1975-11-18 | Medical Eng Corp | Implantable prosthesis having a self-sealing valve |
US4118805A (en) | 1977-02-28 | 1978-10-10 | Codman & Shurtleff, Inc. | Artificial sphincter |
US4364379A (en) * | 1980-05-15 | 1982-12-21 | Finney Roy P | Penile erectile system |
GB2086792B (en) | 1980-11-07 | 1984-12-12 | Microsurgical Administrative S | Gripping devices |
US4899747A (en) | 1981-12-10 | 1990-02-13 | Garren Lloyd R | Method and appartus for treating obesity |
US4416267A (en) | 1981-12-10 | 1983-11-22 | Garren Lloyd R | Method and apparatus for treating obesity |
US4545367A (en) | 1982-07-16 | 1985-10-08 | Cordis Corporation | Detachable balloon catheter and method of use |
US4485805A (en) | 1982-08-24 | 1984-12-04 | Gunther Pacific Limited Of Hong Kong | Weight loss device and method |
FR2534801A1 (en) | 1982-10-21 | 1984-04-27 | Claracq Michel | DEVICE FOR PARTIALLY OCCLUDING A VESSEL, PARTICULARLY OF THE CAUDAL CAVE VEIN, AND CONSTITUENT PART THEREOF |
IL67773A (en) | 1983-01-28 | 1985-02-28 | Antebi E | Tie for tying live tissue and an instrument for performing said tying operation |
US4430392A (en) | 1983-02-11 | 1984-02-07 | Honeywell Inc. | Heat activated vent |
US4607618A (en) | 1983-02-23 | 1986-08-26 | Angelchik Jean P | Method for treatment of morbid obesity |
WO1988000027A1 (en) | 1986-07-09 | 1988-01-14 | Angelchik Jean P | Method for treatment of morbid obesity |
US4648383A (en) | 1985-01-11 | 1987-03-10 | Angelchik Jean P | Peroral apparatus for morbid obesity treatment |
US4636213A (en) | 1985-01-24 | 1987-01-13 | Pakiam Anthony I | Implantable prosthesis |
US4881939A (en) | 1985-02-19 | 1989-11-21 | The Johns Hopkins University | Implantable helical cuff |
DE3516018A1 (en) | 1985-05-02 | 1986-12-18 | Holger 1000 Berlin Kruse | PORTABLE DEVICE FOR DETERMINING THE STOMACH FUNCTION ON THE BASIS OF THE ACIDIC ACID |
US4723547A (en) | 1985-05-07 | 1988-02-09 | C. R. Bard, Inc. | Anti-obesity balloon placement system |
US4598699A (en) | 1985-06-10 | 1986-07-08 | Garren Lloyd R | Endoscopic instrument for removing stomach insert |
US4694827A (en) | 1986-01-14 | 1987-09-22 | Weiner Brian C | Inflatable gastric device for treating obesity and method of using the same |
US4739758A (en) | 1986-05-19 | 1988-04-26 | Criticare Systems, Inc. | Apparatus for stomach cavity reduction |
US4773432A (en) | 1987-02-09 | 1988-09-27 | Schneider-Shiley (Usa) Inc. | Bail-out catheter |
JPS63264078A (en) | 1987-04-22 | 1988-10-31 | オリンパス光学工業株式会社 | Balloon for diet |
JPS63279854A (en) | 1987-05-12 | 1988-11-16 | Olympus Optical Co Ltd | Diet balloon extracting apparatus |
US4930535A (en) | 1987-05-14 | 1990-06-05 | Mcghan Medical Corporation | Folding leaf valve and method of making |
US4844068A (en) | 1987-06-05 | 1989-07-04 | Ethicon, Inc. | Bariatric surgical instrument |
JP2561853B2 (en) | 1988-01-28 | 1996-12-11 | 株式会社ジェイ・エム・エス | Shaped memory molded article and method of using the same |
DE8804765U1 (en) | 1988-04-12 | 1989-05-11 | Witzel, Lothar, Prof. Dr., 1000 Berlin, De | |
US4925446A (en) | 1988-07-06 | 1990-05-15 | Transpharm Group Inc. | Removable inflatable intragastrointestinal device for delivering beneficial agents |
US5308324A (en) | 1989-01-09 | 1994-05-03 | Pilot Cardiovascular Systems, Inc. | Steerable medical device |
US4969899A (en) | 1989-03-08 | 1990-11-13 | Cox-Uphoff International | Inflatable implant |
SE465017B (en) | 1989-11-24 | 1991-07-15 | Lars Knutson | DEVICE FOR SEGMENTAL PERFUSION / ASPIRATION OF THE ENTREPRENEUR |
US5527340A (en) | 1990-04-20 | 1996-06-18 | S & T Marketing Ag | Surgical instrument with gripping portion |
US5074868A (en) | 1990-08-03 | 1991-12-24 | Inamed Development Company | Reversible stoma-adjustable gastric band |
US5226429A (en) | 1991-06-20 | 1993-07-13 | Inamed Development Co. | Laparoscopic gastric band and method |
US5211371A (en) | 1991-07-22 | 1993-05-18 | Advanced Control Technologies, Inc. | Linearly actuated valve |
US5289817A (en) | 1991-08-20 | 1994-03-01 | Linvatec Corporation | Endoscopic surgical retractor |
US5259399A (en) | 1992-03-02 | 1993-11-09 | Alan Brown | Device and method of causing weight loss using removable variable volume intragastric bladder |
US5242398A (en) * | 1992-03-12 | 1993-09-07 | Knoll Charles L | Catheter assembly and related method |
US5255690A (en) | 1992-07-16 | 1993-10-26 | Scimed Life Systems, Inc. | Method and apparatus for proximal support of a guide wire during catheter exchange |
US5972000A (en) | 1992-11-13 | 1999-10-26 | Influence Medical Technologies, Ltd. | Non-linear anchor inserter device and bone anchors |
US5449368A (en) | 1993-02-18 | 1995-09-12 | Kuzmak; Lubomyr I. | Laparoscopic adjustable gastric banding device and method for implantation and removal thereof |
US5601604A (en) | 1993-05-27 | 1997-02-11 | Inamed Development Co. | Universal gastric band |
DE69429670T2 (en) | 1993-08-23 | 2002-08-22 | Boston Scient Corp | IMPROVED BALLOON CATHETER |
US5658298A (en) | 1993-11-09 | 1997-08-19 | Inamed Development Company | Laparoscopic tool |
US5486191A (en) | 1994-02-02 | 1996-01-23 | John Hopkins University | Winged biliary stent |
WO1995023623A1 (en) | 1994-03-04 | 1995-09-08 | Mentor Corporation | Self-sealing injection sites and method of manufacture |
US5540701A (en) | 1994-05-20 | 1996-07-30 | Hugh Sharkey | Passive fixation anastomosis method and device |
US5547458A (en) | 1994-07-11 | 1996-08-20 | Ethicon, Inc. | T-shaped abdominal wall lift with telescoping member |
US5514176A (en) | 1995-01-20 | 1996-05-07 | Vance Products Inc. | Pull apart coil stent |
JP3707822B2 (en) | 1995-03-23 | 2005-10-19 | 富士写真フイルム株式会社 | Image display device |
US5771902A (en) | 1995-09-25 | 1998-06-30 | Regents Of The University Of California | Micromachined actuators/sensors for intratubular positioning/steering |
US6102922A (en) | 1995-09-22 | 2000-08-15 | Kirk Promotions Limited | Surgical method and device for reducing the food intake of patient |
DE19749011A1 (en) | 1996-11-19 | 1998-05-20 | Lang Volker | Micro=valve for one time use has opening closed by plug mounted on resistance plate |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
DE69723955D1 (en) | 1997-04-04 | 2003-09-11 | Christian Peclat | Peristaltic pump |
US5938669A (en) | 1997-05-07 | 1999-08-17 | Klasamed S.A. | Adjustable gastric banding device for contracting a patient's stomach |
US5820584A (en) | 1997-08-28 | 1998-10-13 | Crabb; Jerry A. | Duodenal insert and method of use |
US6183492B1 (en) | 1997-08-28 | 2001-02-06 | Charles C. Hart | Perfusion-isolation catheter apparatus and method |
US6503271B2 (en) | 1998-01-09 | 2003-01-07 | Cordis Corporation | Intravascular device with improved radiopacity |
US6740082B2 (en) | 1998-12-29 | 2004-05-25 | John H. Shadduck | Surgical instruments for treating gastro-esophageal reflux |
US6074341A (en) | 1998-06-09 | 2000-06-13 | Timm Medical Technologies, Inc. | Vessel occlusive apparatus and method |
JP3426510B2 (en) | 1998-07-27 | 2003-07-14 | ペンタックス株式会社 | High frequency snare for endoscope |
US6264700B1 (en) | 1998-08-27 | 2001-07-24 | Endonetics, Inc. | Prosthetic gastroesophageal valve |
FR2783153B1 (en) | 1998-09-14 | 2000-12-01 | Jerome Dargent | GASTRIC CONSTRICTION DEVICE |
WO2000032092A1 (en) | 1998-11-25 | 2000-06-08 | Ball Semiconductor, Inc. | Intraluminal monitoring system |
US6193732B1 (en) | 1999-01-08 | 2001-02-27 | Cardiothoracic System | Surgical clips and apparatus and method for clip placement |
US6322538B1 (en) | 1999-02-18 | 2001-11-27 | Scimed Life Systems, Inc. | Gastro-intestinal tube placement device |
US6290575B1 (en) | 1999-03-01 | 2001-09-18 | John I. Shipp | Surgical ligation clip with increased ligating force |
FR2797181B1 (en) | 1999-08-05 | 2002-05-03 | Richard Cancel | REMOTE GASTRIC BAND DEVICE FOR FORMING A RESTRICTED STOMA OPENING IN THE ESTOMAC |
US6454699B1 (en) | 2000-02-11 | 2002-09-24 | Obtech Medical Ag | Food intake restriction with controlled wireless energy supply |
US6464628B1 (en) | 1999-08-12 | 2002-10-15 | Obtech Medical Ag | Mechanical anal incontinence |
US6733513B2 (en) | 1999-11-04 | 2004-05-11 | Advanced Bioprosthetic Surfaces, Ltd. | Balloon catheter having metal balloon and method of making same |
US6371971B1 (en) | 1999-11-15 | 2002-04-16 | Scimed Life Systems, Inc. | Guidewire filter and methods of use |
AU780359B2 (en) | 1999-11-24 | 2005-03-17 | Innovative Development & Marketing As | Method and device for training pelvic floor muscles |
US6470892B1 (en) | 2000-02-10 | 2002-10-29 | Obtech Medical Ag | Mechanical heartburn and reflux treatment |
WO2001045486A2 (en) | 2000-02-11 | 2001-06-28 | Potencia Medical Ag | Urinary incontinence treatment apparatus |
US6450946B1 (en) | 2000-02-11 | 2002-09-17 | Obtech Medical Ag | Food intake restriction with wireless energy transfer |
MXPA00001922A (en) | 2000-02-24 | 2002-03-08 | De Hayos Garza Andres | Percutaneous intra-gastric balloon catheter for obesity treatment. |
US6503264B1 (en) | 2000-03-03 | 2003-01-07 | Bioenterics Corporation | Endoscopic device for removing an intragastric balloon |
ITPC20000013A1 (en) | 2000-04-13 | 2000-07-13 | Paolo Ferrazzi | INTROVENTRICULAR DEVICE AND RELATED METHOD FOR THE TREATMENT AND CORRECTION OF MYOCARDIOPATHIES. |
US6682473B1 (en) | 2000-04-14 | 2004-01-27 | Solace Therapeutics, Inc. | Devices and methods for attenuation of pressure waves in the body |
EP1066840B1 (en) | 2000-04-28 | 2004-12-29 | Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica | Ventricular assist device |
US6540789B1 (en) | 2000-06-15 | 2003-04-01 | Scimed Life Systems, Inc. | Method for treating morbid obesity |
US7399271B2 (en) | 2004-01-09 | 2008-07-15 | Cardiokinetix, Inc. | Ventricular partitioning device |
US7033373B2 (en) | 2000-11-03 | 2006-04-25 | Satiety, Inc. | Method and device for use in minimally invasive placement of space-occupying intragastric devices |
US6579301B1 (en) | 2000-11-17 | 2003-06-17 | Syntheon, Llc | Intragastric balloon device adapted to be repeatedly varied in volume without external assistance |
WO2002048663A2 (en) | 2000-12-12 | 2002-06-20 | Mini-Mitter Company, Inc. | Digital sensor for miniature medical thermometer, and body temperature monitor |
ES2174749B1 (en) | 2001-02-12 | 2004-08-16 | Luis Miguel Molina Trigueros | GASTRIC CLAMP FOR THE CONDUCT OF VERTICAL GASTROPLASTIA BANDEADA AND BY-PASS GASTRIC TO MINOR CURVING. |
US6702763B2 (en) | 2001-02-28 | 2004-03-09 | Chase Medical, L.P. | Sizing apparatus and method for use during ventricular restoration |
AU2002234439B8 (en) | 2001-03-07 | 2008-09-11 | Telezygology Inc. | A closure with concertina element and processing means |
EP1366716B1 (en) | 2001-03-09 | 2005-04-27 | José Rafael Garza Alvarez | Intragastric balloon assembly |
US6513403B2 (en) | 2001-04-03 | 2003-02-04 | Cray Inc. | Flexible drive rod for access to enclosed locations |
FR2823663B1 (en) | 2001-04-18 | 2004-01-02 | Cousin Biotech | DEVICE FOR TREATING MORBID OBESITY |
US7616996B2 (en) | 2005-09-01 | 2009-11-10 | Intrapace, Inc. | Randomized stimulation of a gastrointestinal organ |
US7020531B1 (en) | 2001-05-01 | 2006-03-28 | Intrapace, Inc. | Gastric device and suction assisted method for implanting a device on a stomach wall |
ES2246323T3 (en) | 2001-05-08 | 2006-02-16 | Alberto Arena | PROPORTIONAL VALVE PROVIDED WITH AN ACTION OF AN ALLOCATION WITH FORM MEMORY. |
US6558400B2 (en) | 2001-05-30 | 2003-05-06 | Satiety, Inc. | Obesity treatment tools and methods |
US6511490B2 (en) | 2001-06-22 | 2003-01-28 | Antoine Jean Henri Robert | Gastric banding device and method |
US20040117031A1 (en) | 2001-08-27 | 2004-06-17 | Stack Richard S. | Satiation devices and methods |
US6675809B2 (en) | 2001-08-27 | 2004-01-13 | Richard S. Stack | Satiation devices and methods |
US6845776B2 (en) | 2001-08-27 | 2005-01-25 | Richard S. Stack | Satiation devices and methods |
US6751491B2 (en) | 2001-09-01 | 2004-06-15 | M Biotech Inc | Analyte measuring biosensor chip using image scanning system |
US6659937B2 (en) | 2001-10-11 | 2003-12-09 | M. Sheldon Polsky | Continent bladder access device |
US6755869B2 (en) | 2001-11-09 | 2004-06-29 | Boston Scientific Corporation | Intragastric prosthesis for the treatment of morbid obesity |
US20030106761A1 (en) | 2001-12-07 | 2003-06-12 | Taylor William Morris | Shape memory alloy wrap spring clutch |
FR2834198B1 (en) | 2001-12-28 | 2004-10-15 | Cie Euro Etude Rech Paroscopie | MEDICAL EXPLANTATION DEVICE |
FR2834202B1 (en) | 2001-12-28 | 2004-03-19 | Cie Euro Etude Rech Paroscopie | MULTI-POCKET INTRA-GASTRIC BALLOON, SURGICAL EXPANSION DEVICE FOR SAID BALLOON AND MANUFACTURING METHOD THEREOF |
US20030153905A1 (en) | 2002-01-25 | 2003-08-14 | Edwards Stuart Denzil | Selective ablation system |
US6733512B2 (en) | 2002-03-07 | 2004-05-11 | Mcghan Jim J. | Self-deflating intragastric balloon |
US6960233B1 (en) | 2002-12-10 | 2005-11-01 | Torax Medical, Inc. | Methods and apparatus for improving the function of biological passages |
FR2840804B1 (en) | 2002-06-13 | 2004-09-17 | Richard Cancel | SYSTEM FOR THE TREATMENT OF OBESITY AND IMPLANT FOR SUCH A SYSTEM |
US6746460B2 (en) | 2002-08-07 | 2004-06-08 | Satiety, Inc. | Intra-gastric fastening devices |
US7338433B2 (en) | 2002-08-13 | 2008-03-04 | Allergan, Inc. | Remotely adjustable gastric banding method |
BR0306183A (en) | 2002-08-28 | 2004-10-19 | Inamed Medical Products Corp | Fatigue Resistant Gastric Banding Device |
US6981978B2 (en) | 2002-08-30 | 2006-01-03 | Satiety, Inc. | Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach |
US7033384B2 (en) | 2002-08-30 | 2006-04-25 | Satiety, Inc. | Stented anchoring of gastric space-occupying devices |
US7214233B2 (en) | 2002-08-30 | 2007-05-08 | Satiety, Inc. | Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach |
ES2291405T3 (en) | 2002-09-04 | 2008-03-01 | Endoart S.A. | SURGICAL RING PROVIDED WITH A REMOTE CONTROL SYSTEM AND REVERSIBLE IN THE VARIATION OF YOUR DIAMETER. |
ES2295272T3 (en) | 2002-09-04 | 2008-04-16 | Endoart S.A. | CLOSURE SYSTEM FOR SURGICAL RING. |
US7220237B2 (en) | 2002-10-23 | 2007-05-22 | Satiety, Inc. | Method and device for use in endoscopic organ procedures |
US8070743B2 (en) | 2002-11-01 | 2011-12-06 | Valentx, Inc. | Devices and methods for attaching an endolumenal gastrointestinal implant |
US7037344B2 (en) | 2002-11-01 | 2006-05-02 | Valentx, Inc. | Apparatus and methods for treatment of morbid obesity |
US9060844B2 (en) | 2002-11-01 | 2015-06-23 | Valentx, Inc. | Apparatus and methods for treatment of morbid obesity |
US7837669B2 (en) | 2002-11-01 | 2010-11-23 | Valentx, Inc. | Devices and methods for endolumenal gastrointestinal bypass |
US7794447B2 (en) | 2002-11-01 | 2010-09-14 | Valentx, Inc. | Gastrointestinal sleeve device and methods for treatment of morbid obesity |
US7766973B2 (en) | 2005-01-19 | 2010-08-03 | Gi Dynamics, Inc. | Eversion resistant sleeves |
US7608114B2 (en) | 2002-12-02 | 2009-10-27 | Gi Dynamics, Inc. | Bariatric sleeve |
US7025791B2 (en) | 2002-12-02 | 2006-04-11 | Gi Dynamics, Inc. | Bariatric sleeve |
US7695446B2 (en) | 2002-12-02 | 2010-04-13 | Gi Dynamics, Inc. | Methods of treatment using a bariatric sleeve |
JP4980569B2 (en) | 2002-12-02 | 2012-07-18 | ジーアイ・ダイナミックス・インコーポレーテッド | Gastrointestinal implant device and delivery system for placing the device in the body |
US20040143342A1 (en) | 2003-01-16 | 2004-07-22 | Stack Richard S. | Satiation pouches and methods of use |
US7613515B2 (en) | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
US7291160B2 (en) | 2003-03-17 | 2007-11-06 | Delegge Rebecca | Intragastric catheter |
US6981980B2 (en) | 2003-03-19 | 2006-01-03 | Phagia Technology | Self-inflating intragastric volume-occupying device |
FR2852821B1 (en) | 2003-03-31 | 2007-06-01 | Cie Euro Etude Rech Paroscopie | PARYLENE-COATED INTRA-GASTRIC BALLOON, PROCESS FOR PRODUCING SUCH BALLOON AND USE OF PARYLENE FOR COATING INTRA-GASTRIC BALLOON |
FR2855744B1 (en) | 2003-06-04 | 2006-04-14 | Cie Euro Etude Rech Paroscopie | SURGICAL RING WITH IMPROVED CLOSURE SYSTEM |
ATE438365T1 (en) | 2003-06-20 | 2009-08-15 | Allergan Inc | TWO-WAY SLOT VALVE |
BR0302240B8 (en) | 2003-06-24 | 2013-02-19 | semi-stationary balloon in the gastric antrum with anchor rod for weight loss induction in humans. | |
US9498366B2 (en) | 2003-07-28 | 2016-11-22 | Baronova, Inc. | Devices and methods for pyloric anchoring |
US20090259236A2 (en) | 2003-07-28 | 2009-10-15 | Baronova, Inc. | Gastric retaining devices and methods |
US6994095B2 (en) | 2003-07-28 | 2006-02-07 | Medventure Associates Iv | Pyloric valve corking device and method |
US8535344B2 (en) | 2003-09-12 | 2013-09-17 | Rubicon Medical, Inc. | Methods, systems, and devices for providing embolic protection and removing embolic material |
US8206456B2 (en) | 2003-10-10 | 2012-06-26 | Barosense, Inc. | Restrictive and/or obstructive implant system for inducing weight loss |
US7914543B2 (en) | 2003-10-14 | 2011-03-29 | Satiety, Inc. | Single fold device for tissue fixation |
FR2861288B1 (en) | 2003-10-23 | 2006-02-10 | Cie Euro Etude Rech Paroscopie | INTRA-GASTRIC BALLOON LESTE, USE OF AN ABSORBENT BODY AND / OR DENSED SOLID BODIES TO FORM A LEST WITHIN SUCH A BALLOON |
WO2005060882A1 (en) | 2003-12-09 | 2005-07-07 | Gi Dynamics, Inc. | Apparatus to be anchored within the gastrointestinal tract and anchoring method |
US8057420B2 (en) | 2003-12-09 | 2011-11-15 | Gi Dynamics, Inc. | Gastrointestinal implant with drawstring |
FR2866557B1 (en) | 2004-02-20 | 2006-08-25 | Cie Euro Etude Rech Paroscopie | INTRA-GASTRIC POCKET BALL WITH A SHUTTER ASSEMBLY IMPROVED ON THE SAME POCKET |
US7931693B2 (en) | 2004-02-26 | 2011-04-26 | Endosphere, Inc. | Method and apparatus for reducing obesity |
US8147561B2 (en) | 2004-02-26 | 2012-04-03 | Endosphere, Inc. | Methods and devices to curb appetite and/or reduce food intake |
US20050197714A1 (en) | 2004-03-02 | 2005-09-08 | Sayet Peter H. | System, system devices, and methods for regulating nutrient absorption and caloric intake |
EP1732635B1 (en) | 2004-03-18 | 2011-07-27 | Allergan, Inc. | Apparatus for volume adjustment of intragastric balloons |
WO2005097012A2 (en) | 2004-03-26 | 2005-10-20 | Satiety, Inc. | Systems and methods for treating obesity |
EP1744804A4 (en) | 2004-05-03 | 2009-11-04 | Fulfillium Inc | Method and system for gastric volume control |
BRPI0511056A (en) | 2004-05-14 | 2007-11-27 | Bard Inc C R | gastric balloon devices and methods of use |
US20050261711A1 (en) | 2004-05-24 | 2005-11-24 | Olympus Corporation | Treatment method and endoscope apparatus |
US7645285B2 (en) | 2004-05-26 | 2010-01-12 | Idx Medical, Ltd | Apparatus and methods for occluding a hollow anatomical structure |
US7803195B2 (en) * | 2004-06-03 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
US20050277975A1 (en) | 2004-06-09 | 2005-12-15 | Usgi Medical Corp. | Methods and apparatus for creating a working space within a body lumen or cavity |
US7678135B2 (en) | 2004-06-09 | 2010-03-16 | Usgi Medical, Inc. | Compressible tissue anchor assemblies |
US7837643B2 (en) | 2004-07-09 | 2010-11-23 | Gi Dynamics, Inc. | Methods and devices for placing a gastrointestinal sleeve |
US20060025799A1 (en) | 2004-07-27 | 2006-02-02 | Patrick Basu | Endoscopically placed gastric balloon (EPGB) device and method for treating obesity involving the same |
US20060069403A1 (en) | 2004-09-21 | 2006-03-30 | Shalon Ventures, Inc. | Tissue expansion devices |
WO2006035446A2 (en) | 2004-09-30 | 2006-04-06 | Duocure, Inc. | Device and method for treating weight disorders |
US20070078476A1 (en) | 2004-10-12 | 2007-04-05 | Hull Wendell C Sr | Overweight control apparatuses for insertion into the stomach |
ES2582334T3 (en) | 2004-10-15 | 2016-09-12 | Bfkw, Llc | Bariatric device |
US20060106288A1 (en) | 2004-11-17 | 2006-05-18 | Roth Alex T | Remote tissue retraction device |
WO2006063593A2 (en) | 2004-12-14 | 2006-06-22 | Rune Wessel Weltlesen | A system and a method for treating of obesity by use of an intragastric balloon |
US7771382B2 (en) | 2005-01-19 | 2010-08-10 | Gi Dynamics, Inc. | Resistive anti-obesity devices |
JP2008537898A (en) | 2005-02-11 | 2008-10-02 | ミカーディア コーポレーション | Dynamically adjustable gastric implant and method for treating obesity using the same |
WO2006090018A1 (en) | 2005-02-24 | 2006-08-31 | Compagnie Europeene D'etude Et De Recherche De Dispositifs Pour L'implantation Par Laparoscopie | Intragastric balloon with extraction reinforcement |
US7699863B2 (en) | 2005-03-01 | 2010-04-20 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
CA2601426A1 (en) | 2005-03-18 | 2006-09-28 | Thomas D. Egan | Gastric bypass prosthesis fixation system and method for treatment of obesity |
DE602006011721D1 (en) | 2005-03-24 | 2010-03-04 | Cook Inc | INTERCHANGEABLE DISCHARGE SYSTEM WITH DISTAL PROTECTION |
WO2006111961A2 (en) | 2005-04-18 | 2006-10-26 | Eli Bar | Methods and devices for limiting gastric expansion |
US9345604B2 (en) | 2005-05-02 | 2016-05-24 | Almuhannad Alfrhan | Percutaneous intragastric balloon device and method |
US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
US7871416B2 (en) | 2005-07-22 | 2011-01-18 | Phillips Edward H | Clamp device to plicate the stomach |
WO2007017880A2 (en) | 2005-08-11 | 2007-02-15 | Stimplant Ltd. | Implantable device for obesity prevention |
JP4880262B2 (en) | 2005-08-11 | 2012-02-22 | オリンパスメディカルシステムズ株式会社 | Intragastric balloon |
JP2009507617A (en) | 2005-09-14 | 2009-02-26 | ネオガイド システムズ, インコーポレイテッド | Method and apparatus for performing transluminal and other operations |
FR2892296A1 (en) | 2005-10-21 | 2007-04-27 | Christophe Bastid | Intragastric balloon for e.g. man, has tubing with two canals and retrieved via endoscopic channel by using biopsy forceps, where canals of tubing have volume that is modified and tubing is reintroduced in stomach of patient |
US20070100369A1 (en) | 2005-10-31 | 2007-05-03 | Cragg Andrew H | Intragastric space filler |
EP3056173A1 (en) | 2005-10-31 | 2016-08-17 | ReShape Medical Corporation | Intragastric space filler |
US20070100368A1 (en) | 2005-10-31 | 2007-05-03 | Quijano Rodolfo C | Intragastric space filler |
US8936590B2 (en) | 2005-11-09 | 2015-01-20 | The Invention Science Fund I, Llc | Acoustically controlled reaction device |
ATE529077T1 (en) | 2005-12-22 | 2011-11-15 | Wilson Cook Medical Inc | STOMACH Pouch FOR THE TREATMENT OF OBESITY |
WO2007075978A2 (en) | 2005-12-22 | 2007-07-05 | Wilson-Cook Medical Inc. | Coiled intragastric member for treating obesity |
US8043206B2 (en) | 2006-01-04 | 2011-10-25 | Allergan, Inc. | Self-regulating gastric band with pressure data processing |
US20070185374A1 (en) | 2006-01-17 | 2007-08-09 | Ellipse Technologies, Inc. | Two-way adjustable implant |
JP5280211B2 (en) | 2006-02-03 | 2013-09-04 | バロノヴァ,インク. | Apparatus and method for gastrointestinal stimulation |
US8377072B2 (en) | 2006-02-06 | 2013-02-19 | Depuy Spine, Inc. | Medical device installation tool |
ES2592316T3 (en) | 2006-03-28 | 2016-11-29 | Spatz-Fgia Inc | Floating gastrointestinal anchor |
US8152710B2 (en) | 2006-04-06 | 2012-04-10 | Ethicon Endo-Surgery, Inc. | Physiological parameter analysis for an implantable restriction device and a data logger |
US8187297B2 (en) | 2006-04-19 | 2012-05-29 | Vibsynt, Inc. | Devices and methods for treatment of obesity |
US8070768B2 (en) | 2006-04-19 | 2011-12-06 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
WO2007127209A2 (en) | 2006-04-25 | 2007-11-08 | Valentx, Inc. | Methods and devices for gastrointestinal stimulation |
US20070288033A1 (en) | 2006-06-09 | 2007-12-13 | Allergan, Inc. | Intragastric balloon retrieval mechanisms |
US20090299486A1 (en) | 2006-06-29 | 2009-12-03 | Slimedics Ltd. | Gastrointestinal Prostheses |
IL176889A0 (en) | 2006-07-16 | 2006-10-31 | Medigus Ltd | Devices and methods for treating morbid obesity |
US20080058840A1 (en) | 2006-09-01 | 2008-03-06 | Albrecht Thomas E | Implantable coil for insertion into a hollow body organ |
US20080167610A1 (en) | 2006-09-25 | 2008-07-10 | Valentx, Inc. | Toposcopic methods and devices for delivering a sleeve having axially compressed and elongate configurations |
US9326877B2 (en) | 2006-09-29 | 2016-05-03 | Apollo Endosurgery, Inc. | Apparatus and method for intragastric balloon with in situ adjustment means |
US7628442B1 (en) | 2006-10-25 | 2009-12-08 | Truxedo, Inc. | Quick release clamp for tonneau cover |
US20100241178A1 (en) * | 2008-06-02 | 2010-09-23 | Loma Vista Medical, Inc. | Inflatable medical devices |
US8926648B2 (en) | 2007-02-13 | 2015-01-06 | Brian Charles Weiner | Multi-method and multi-apparatus for treating obesity |
WO2008101048A2 (en) | 2007-02-14 | 2008-08-21 | Bfkw, Llc | Bariatric device and method |
US8529431B2 (en) | 2007-02-14 | 2013-09-10 | Bfkw, Llc | Bariatric device and method |
US8114045B2 (en) | 2007-03-02 | 2012-02-14 | Cook Medical Technologies Llc | Apparatus and methods for delaying gastric emptying to treat obesity |
US20090082644A1 (en) | 2007-03-15 | 2009-03-26 | Jiayi Li | Devices, Systems, Kits and Methods for Treatment of Obesity |
EP2134303A1 (en) * | 2007-03-29 | 2009-12-23 | Jaime Vargas | Intragastric implant devices |
US8226602B2 (en) | 2007-03-30 | 2012-07-24 | Reshape Medical, Inc. | Intragastric balloon system and therapeutic processes and products |
US20080249635A1 (en) | 2007-04-05 | 2008-10-09 | Barry Weitzner | Gastric filler devices for obesity therapy |
US20080255678A1 (en) | 2007-04-13 | 2008-10-16 | Cully Edward H | Medical apparatus and method of making the same |
US20080255601A1 (en) | 2007-04-13 | 2008-10-16 | Allergan, Inc. | Apparatus and method for remote deflation of intragastric balloon |
WO2008132745A2 (en) | 2007-04-30 | 2008-11-06 | Spatz Fgia, Inc. | Non-endoscopic insertion and removal of a device |
DE102007025312A1 (en) | 2007-05-25 | 2008-11-27 | Q Medical International Ag | Intragastric stomach use for the treatment of obesity |
EP2164558A4 (en) | 2007-06-08 | 2010-08-04 | Valentx Inc | Methods and devices for intragastric support of functional or prosthetic gastrointestinal devices |
US20080306506A1 (en) | 2007-06-11 | 2008-12-11 | Leatherman Dennis A | Self-inflating and deflating intragastric balloon implant device |
WO2009011824A1 (en) | 2007-07-13 | 2009-01-22 | The Brigham And Women's Hospital, Inc. | System and method for hernia mesh fixation |
EP2185084A4 (en) | 2007-09-07 | 2017-08-09 | Baronova, Inc. | Device for intermittently obstructing a gastric opening and method of use |
US20090093767A1 (en) | 2007-10-04 | 2009-04-09 | Brian Kelleher | Devices and methods for endolumenal therapy |
WO2009048949A1 (en) * | 2007-10-09 | 2009-04-16 | Wilson-Cook Medical, Inc. | Anastomosis plug for bariatric surgery |
FR2922095B1 (en) * | 2007-10-16 | 2010-09-03 | Cie Euro Etude Rech Paroscopie | DEVICE FOR INFLATION OF A SURGICAL IMPLANT |
EP2224887A2 (en) | 2007-10-23 | 2010-09-08 | Allergan, Inc. | Pressure sensing intragastric balloon |
US8016880B2 (en) | 2007-11-16 | 2011-09-13 | Medtronic Vascular, Inc. | Stent having spiral channel for drug delivery |
CN101450018B (en) | 2007-11-28 | 2010-09-08 | 王涛 | Recoverable valve bracket |
EP2240138B1 (en) | 2008-01-29 | 2021-07-21 | Implantica Patent Ltd. | Apparatus for treating obesity |
US20090259246A1 (en) | 2008-04-14 | 2009-10-15 | Sherif Eskaros | Intragastric Volume-Occupying Device |
US20100081991A1 (en) * | 2008-09-30 | 2010-04-01 | Tyco Healthcare Group Lp | Skin level device for use with gastrostomy tube |
US8317677B2 (en) | 2008-10-06 | 2012-11-27 | Allergan, Inc. | Mechanical gastric band with cushions |
US8162969B2 (en) | 2008-10-16 | 2012-04-24 | Obalon Therapeutics, Inc. | Intragastric device |
US20100100115A1 (en) | 2008-10-20 | 2010-04-22 | Wilson-Cook Medical Inc. | Foam filled intragastric balloon for treating obesity |
US9364362B2 (en) | 2008-10-21 | 2016-06-14 | General Electric Company | Implantable device system |
CN102481490A (en) | 2008-12-27 | 2012-05-30 | 约翰·汉考克 | High specific gravity intragastric device |
US20120116285A1 (en) | 2008-12-27 | 2012-05-10 | Duggirala Chandra S | Devices for treating obesity and methods of using those devices |
FR2941617B1 (en) | 2009-02-04 | 2012-06-29 | Endalis | INTRA-GASTRIC BALLOON. |
EP2414026A2 (en) | 2009-03-31 | 2012-02-08 | Onciomed, Inc. | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
US8100932B2 (en) | 2009-03-31 | 2012-01-24 | Onciomed, Inc. | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
US20100249822A1 (en) | 2009-03-31 | 2010-09-30 | Raj Nihalani | Method and apparatus for treating obesity and controlling weight gain using adjustable intragastric devices |
JP2012522595A (en) | 2009-04-03 | 2012-09-27 | メタモディクス インコーポレイテッド | Modular gastrointestinal prosthesis |
US8317526B2 (en) | 2009-04-14 | 2012-11-27 | Halex Co. | Ground clamp |
US20100286628A1 (en) | 2009-05-07 | 2010-11-11 | Rainbow Medical Ltd | Gastric anchor |
US20100305590A1 (en) | 2009-05-29 | 2010-12-02 | Gi Dynamics, Inc. | Transpyloric Anchoring |
CA2778590A1 (en) | 2009-10-21 | 2011-04-28 | Innovelle, Llc | Bariatric device and method for weight loss |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
ES2593753T3 (en) | 2010-10-19 | 2016-12-13 | Apollo Endosurgery, Inc. | Duodenal sleeve with anchor without perforation |
-
2011
- 2011-10-17 US US13/275,224 patent/US9498365B2/en active Active
- 2011-10-18 ES ES11773972.2T patent/ES2562035T3/en active Active
- 2011-10-18 EP EP11773972.2A patent/EP2629711B1/en not_active Not-in-force
- 2011-10-18 EP EP15202671.2A patent/EP3023081A1/en not_active Withdrawn
- 2011-10-18 WO PCT/US2011/056605 patent/WO2012054410A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084061A (en) | 1987-09-25 | 1992-01-28 | Gau Fred C | Intragastric balloon with improved valve locating means |
WO2006138480A1 (en) * | 2005-06-16 | 2006-12-28 | Hively Robert L | Gastric bariatric apparatus with selective inflation and safety features |
US20090149879A1 (en) * | 2007-12-10 | 2009-06-11 | Dillon Travis E | Dynamic volume displacement weight loss device |
WO2010087757A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | Obesity treatment |
Also Published As
Publication number | Publication date |
---|---|
WO2012054410A2 (en) | 2012-04-26 |
EP2629711A2 (en) | 2013-08-28 |
US9498365B2 (en) | 2016-11-22 |
US20120191125A1 (en) | 2012-07-26 |
ES2562035T3 (en) | 2016-03-02 |
WO2012054410A3 (en) | 2012-08-02 |
EP2629711B1 (en) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9498365B2 (en) | Intragastric implants with multiple fluid chambers | |
US9956105B2 (en) | Upper stomach gastric implants | |
US9668901B2 (en) | Intragastric implants with duodenal anchors | |
US9095405B2 (en) | Space-filling intragastric implants with fluid flow | |
EP2629713B1 (en) | Stomach-spanning gastric implants | |
US20120095497A1 (en) | Non-inflatable gastric implants and systems | |
US9198790B2 (en) | Upper stomach gastric implants | |
US9398969B2 (en) | Upper stomach gastric implants | |
US20170065444A1 (en) | Variable Size Intragastric Implant Devices | |
US20160113798A1 (en) | Elevating Stomach Stimulation Device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AC | Divisional application: reference to earlier application |
Ref document number: 2629711 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DOMINGUEZ, ZACHARY P. Inventor name: MUDD, CHRISTOPHER S. Inventor name: BABKES, MITCHELL H. Inventor name: OLROYD, CRAIG Inventor name: D'AUGUSTA, JONATHAN M. |
|
17P | Request for examination filed |
Effective date: 20160831 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MUDD, CHRISTOPHER S. Inventor name: OLROYD, CRAIG Inventor name: DOMINGUEZ, ZACHARY P. Inventor name: BABKES, MITCHELL H. Inventor name: D'AUGUSTA, JONATHAN M. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170503 |